<?xml version="1.0"?>
<presentation title="ClinPhapmEdi2017" width="720.0000000" height="540.0000000" thmbWidth="78.0000000" thmbHeight="59.0000000" frameRate="24.0000000" looping="0" startingSlideShow="" pptVersion="2016" type="compound" hasExternalAudio="0" uid="{D0ADD9BC-5BCE-4B01-85F9-188A7AEC90E6}">
	<presenters/>
	<references/>
	<soundAssets/>
	<sharedAssetsLibrary src="assets.swf"/>
	<graphicAssets>
		<graphicAsset id="imgAsset0" src="thmb1.swf" embedded="0"/>
		<graphicAsset id="imgAsset1" src="thmb2.swf" embedded="0"/>
		<graphicAsset id="imgAsset2" src="thmb3.swf" embedded="0"/>
		<graphicAsset id="imgAsset3" src="thmb4.swf" embedded="0"/>
		<graphicAsset id="imgAsset4" src="thmb5.swf" embedded="0"/>
		<graphicAsset id="imgAsset5" src="thmb6.swf" embedded="0"/>
		<graphicAsset id="imgAsset6" src="thmb7.swf" embedded="0"/>
		<graphicAsset id="imgAsset7" src="thmb8.swf" embedded="0"/>
		<graphicAsset id="imgAsset8" src="thmb9.swf" embedded="0"/>
		<graphicAsset id="imgAsset9" src="thmb10.swf" embedded="0"/>
		<graphicAsset id="imgAsset10" src="thmb11.swf" embedded="0"/>
		<graphicAsset id="imgAsset11" src="thmb12.swf" embedded="0"/>
		<graphicAsset id="imgAsset12" src="thmb13.swf" embedded="0"/>
		<graphicAsset id="imgAsset13" src="thmb14.swf" embedded="0"/>
		<graphicAsset id="imgAsset14" src="thmb15.swf" embedded="0"/>
		<graphicAsset id="imgAsset15" src="thmb16.swf" embedded="0"/>
		<graphicAsset id="imgAsset16" src="thmb17.swf" embedded="0"/>
		<graphicAsset id="imgAsset17" src="thmb18.swf" embedded="0"/>
		<graphicAsset id="imgAsset18" src="thmb19.swf" embedded="0"/>
		<graphicAsset id="imgAsset19" src="thmb20.swf" embedded="0"/>
		<graphicAsset id="imgAsset20" src="thmb21.swf" embedded="0"/>
		<graphicAsset id="imgAsset21" src="thmb22.swf" embedded="0"/>
		<graphicAsset id="imgAsset22" src="thmb23.swf" embedded="0"/>
		<graphicAsset id="imgAsset23" src="thmb24.swf" embedded="0"/>
		<graphicAsset id="imgAsset24" src="thmb25.swf" embedded="0"/>
		<graphicAsset id="imgAsset25" src="thmb26.swf" embedded="0"/>
		<graphicAsset id="imgAsset26" src="thmb27.swf" embedded="0"/>
		<graphicAsset id="imgAsset27" src="thmb28.swf" embedded="0"/>
		<graphicAsset id="imgAsset28" src="thmb29.swf" embedded="0"/>
		<graphicAsset id="imgAsset29" src="thmb30.swf" embedded="0"/>
		<graphicAsset id="imgAsset30" src="thmb31.swf" embedded="0"/>
		<graphicAsset id="imgAsset31" src="thmb32.swf" embedded="0"/>
		<graphicAsset id="imgAsset32" src="thmb33.swf" embedded="0"/>
		<graphicAsset id="imgAsset33" src="thmb34.swf" embedded="0"/>
		<graphicAsset id="imgAsset34" src="thmb35.swf" embedded="0"/>
		<graphicAsset id="imgAsset35" src="thmb36.swf" embedded="0"/>
		<graphicAsset id="imgAsset36" src="thmb37.swf" embedded="0"/>
		<graphicAsset id="imgAsset37" src="thmb38.swf" embedded="0"/>
		<graphicAsset id="imgAsset38" src="thmb39.swf" embedded="0"/>
		<graphicAsset id="imgAsset39" src="thmb40.swf" embedded="0"/>
		<graphicAsset id="imgAsset40" src="thmb41.swf" embedded="0"/>
		<graphicAsset id="imgAsset41" src="thmb42.swf" embedded="0"/>
		<graphicAsset id="imgAsset42" src="thmb43.swf" embedded="0"/>
		<graphicAsset id="imgAsset43" src="thmb44.swf" embedded="0"/>
		<graphicAsset id="imgAsset44" src="thmb45.swf" embedded="0"/>
		<graphicAsset id="imgAsset45" src="thmb46.swf" embedded="0"/>
		<graphicAsset id="imgAsset46" src="thmb47.swf" embedded="0"/>
		<graphicAsset id="imgAsset47" src="thmb48.swf" embedded="0"/>
		<graphicAsset id="imgAsset48" src="thmb49.swf" embedded="0"/>
		<graphicAsset id="imgAsset49" src="thmb50.swf" embedded="0"/>
		<graphicAsset id="imgAsset50" src="thmb51.swf" embedded="0"/>
		<graphicAsset id="imgAsset51" src="thmb52.swf" embedded="0"/>
		<graphicAsset id="imgAsset52" src="thmb53.swf" embedded="0"/>
		<graphicAsset id="imgAsset53" src="thmb54.swf" embedded="0"/>
		<graphicAsset id="imgAsset54" src="thmb55.swf" embedded="0"/>
		<graphicAsset id="imgAsset55" src="thmb56.swf" embedded="0"/>
		<graphicAsset id="imgAsset56" src="thmb57.swf" embedded="0"/>
		<graphicAsset id="imgAsset57" src="thmb58.swf" embedded="0"/>
		<graphicAsset id="imgAsset58" src="thmb59.swf" embedded="0"/>
		<graphicAsset id="imgAsset59" src="thmb60.swf" embedded="0"/>
		<graphicAsset id="imgAsset60" src="thmb61.swf" embedded="0"/>
		<graphicAsset id="imgAsset61" src="thmb62.swf" embedded="0"/>
		<graphicAsset id="imgAsset62" src="thmb63.swf" embedded="0"/>
		<graphicAsset id="imgAsset63" src="thmb64.swf" embedded="0"/>
		<graphicAsset id="imgAsset64" src="thmb65.swf" embedded="0"/>
		<graphicAsset id="imgAsset65" src="thmb66.swf" embedded="0"/>
		<graphicAsset id="imgAsset66" src="thmb67.swf" embedded="0"/>
		<graphicAsset id="imgAsset67" src="thmb68.swf" embedded="0"/>
		<graphicAsset id="imgAsset68" src="thmb69.swf" embedded="0"/>
		<graphicAsset id="imgAsset69" src="thmb70.swf" embedded="0"/>
		<graphicAsset id="imgAsset70" src="thmb71.swf" embedded="0"/>
		<graphicAsset id="imgAsset71" src="thmb72.swf" embedded="0"/>
		<graphicAsset id="imgAsset72" src="thmb73.swf" embedded="0"/>
		<graphicAsset id="imgAsset73" src="thmb74.swf" embedded="0"/>
		<graphicAsset id="imgAsset74" src="thmb75.swf" embedded="0"/>
		<graphicAsset id="imgAsset75" src="thmb76.swf" embedded="0"/>
		<graphicAsset id="imgAsset76" src="thmb77.swf" embedded="0"/>
		<graphicAsset id="imgAsset77" src="thmb78.swf" embedded="0"/>
		<graphicAsset id="imgAsset78" src="thmb79.swf" embedded="0"/>
		<graphicAsset id="imgAsset79" src="thmb80.swf" embedded="0"/>
		<graphicAsset id="imgAsset80" src="thmb81.swf" embedded="0"/>
		<graphicAsset id="imgAsset81" src="thmb82.swf" embedded="0"/>
		<graphicAsset id="imgAsset82" src="thmb83.swf" embedded="0"/>
		<graphicAsset id="imgAsset83" src="thmb84.swf" embedded="0"/>
		<graphicAsset id="imgAsset84" src="thmb85.swf" embedded="0"/>
		<graphicAsset id="imgAsset85" src="thmb86.swf" embedded="0"/>
		<graphicAsset id="imgAsset86" src="thmb87.swf" embedded="0"/>
		<graphicAsset id="imgAsset87" src="thmb88.swf" embedded="0"/>
		<graphicAsset id="imgAsset88" src="thmb89.swf" embedded="0"/>
		<graphicAsset id="imgAsset89" src="thmb90.swf" embedded="0"/>
		<graphicAsset id="imgAsset90" src="thmb91.swf" embedded="0"/>
		<graphicAsset id="imgAsset91" src="thmb92.swf" embedded="0"/>
		<graphicAsset id="imgAsset92" src="thmb93.swf" embedded="0"/>
		<graphicAsset id="imgAsset93" src="thmb94.swf" embedded="0"/>
		<graphicAsset id="imgAsset94" src="thmb95.swf" embedded="0"/>
		<graphicAsset id="imgAsset95" src="thmb96.swf" embedded="0"/>
		<graphicAsset id="imgAsset96" src="thmb97.swf" embedded="0"/>
		<graphicAsset id="imgAsset97" src="thmb98.swf" embedded="0"/>
		<graphicAsset id="imgAsset98" src="thmb99.swf" embedded="0"/>
		<graphicAsset id="imgAsset99" src="thmb100.swf" embedded="0"/>
		<graphicAsset id="imgAsset100" src="thmb101.swf" embedded="0"/>
		<graphicAsset id="imgAsset101" src="thmb102.swf" embedded="0"/>
		<graphicAsset id="imgAsset102" src="thmb103.swf" embedded="0"/>
		<graphicAsset id="imgAsset103" src="thmb104.swf" embedded="0"/>
		<graphicAsset id="imgAsset104" src="thmb105.swf" embedded="0"/>
		<graphicAsset id="imgAsset105" src="thmb106.swf" embedded="0"/>
		<graphicAsset id="imgAsset106" src="thmb107.swf" embedded="0"/>
		<graphicAsset id="imgAsset107" src="thmb108.swf" embedded="0"/>
		<graphicAsset id="imgAsset108" src="thmb109.swf" embedded="0"/>
		<graphicAsset id="imgAsset109" src="thmb110.swf" embedded="0"/>
		<graphicAsset id="imgAsset110" src="thmb111.swf" embedded="0"/>
		<graphicAsset id="imgAsset111" src="thmb112.swf" embedded="0"/>
		<graphicAsset id="imgAsset112" src="thmb113.swf" embedded="0"/>
		<graphicAsset id="imgAsset113" src="thmb114.swf" embedded="0"/>
		<graphicAsset id="imgAsset114" src="thmb115.swf" embedded="0"/>
		<graphicAsset id="imgAsset115" src="thmb116.swf" embedded="0"/>
		<graphicAsset id="imgAsset116" src="thmb117.swf" embedded="0"/>
		<graphicAsset id="imgAsset117" src="thmb118.swf" embedded="0"/>
		<graphicAsset id="imgAsset118" src="thmb119.swf" embedded="0"/>
		<graphicAsset id="imgAsset119" src="thmb120.swf" embedded="0"/>
		<graphicAsset id="imgAsset120" src="thmb121.swf" embedded="0"/>
		<graphicAsset id="imgAsset121" src="thmb122.swf" embedded="0"/>
		<graphicAsset id="imgAsset122" src="thmb123.swf" embedded="0"/>
		<graphicAsset id="imgAsset123" src="thmb124.swf" embedded="0"/>
		<graphicAsset id="imgAsset124" src="thmb125.swf" embedded="0"/>
		<graphicAsset id="imgAsset125" src="thmb126.swf" embedded="0"/>
		<graphicAsset id="imgAsset126" src="thmb127.swf" embedded="0"/>
		<graphicAsset id="imgAsset127" src="thmb128.swf" embedded="0"/>
		<graphicAsset id="imgAsset128" src="thmb129.swf" embedded="0"/>
		<graphicAsset id="imgAsset129" src="thmb130.swf" embedded="0"/>
		<graphicAsset id="imgAsset130" src="thmb131.swf" embedded="0"/>
		<graphicAsset id="imgAsset131" src="thmb132.swf" embedded="0"/>
		<graphicAsset id="imgAsset132" src="thmb133.swf" embedded="0"/>
		<graphicAsset id="imgAsset133" src="thmb134.swf" embedded="0"/>
		<graphicAsset id="imgAsset134" src="thmb135.swf" embedded="0"/>
		<graphicAsset id="imgAsset135" src="thmb136.swf" embedded="0"/>
		<graphicAsset id="imgAsset136" src="thmb137.swf" embedded="0"/>
		<graphicAsset id="imgAsset137" src="thmb138.swf" embedded="0"/>
		<graphicAsset id="imgAsset138" src="thmb139.swf" embedded="0"/>
		<graphicAsset id="imgAsset139" src="thmb140.swf" embedded="0"/>
		<graphicAsset id="imgAsset140" src="thmb141.swf" embedded="0"/>
		<graphicAsset id="imgAsset141" src="thmb142.swf" embedded="0"/>
		<graphicAsset id="imgAsset142" src="thmb143.swf" embedded="0"/>
		<graphicAsset id="imgAsset143" src="thmb144.swf" embedded="0"/>
		<graphicAsset id="imgAsset144" src="thmb145.swf" embedded="0"/>
		<graphicAsset id="imgAsset145" src="thmb146.swf" embedded="0"/>
		<graphicAsset id="imgAsset146" src="thmb147.swf" embedded="0"/>
		<graphicAsset id="imgAsset147" src="thmb148.swf" embedded="0"/>
		<graphicAsset id="imgAsset148" src="thmb149.swf" embedded="0"/>
		<graphicAsset id="imgAsset149" src="thmb150.swf" embedded="0"/>
		<graphicAsset id="imgAsset150" src="thmb151.swf" embedded="0"/>
		<graphicAsset id="imgAsset151" src="thmb152.swf" embedded="0"/>
		<graphicAsset id="imgAsset152" src="thmb153.swf" embedded="0"/>
		<graphicAsset id="imgAsset153" src="thmb154.swf" embedded="0"/>
		<graphicAsset id="imgAsset154" src="thmb155.swf" embedded="0"/>
		<graphicAsset id="imgAsset155" src="thmb156.swf" embedded="0"/>
		<graphicAsset id="imgAsset156" src="thmb157.swf" embedded="0"/>
		<graphicAsset id="imgAsset157" src="thmb158.swf" embedded="0"/>
		<graphicAsset id="imgAsset158" src="thmb159.swf" embedded="0"/>
		<graphicAsset id="imgAsset159" src="thmb160.swf" embedded="0"/>
		<graphicAsset id="imgAsset160" src="thmb161.swf" embedded="0"/>
		<graphicAsset id="imgAsset161" src="thmb162.swf" embedded="0"/>
		<graphicAsset id="imgAsset162" src="thmb163.swf" embedded="0"/>
		<graphicAsset id="imgAsset163" src="thmb164.swf" embedded="0"/>
		<graphicAsset id="imgAsset164" src="thmb165.swf" embedded="0"/>
		<graphicAsset id="imgAsset165" src="thmb166.swf" embedded="0"/>
		<graphicAsset id="imgAsset166" src="thmb167.swf" embedded="0"/>
		<graphicAsset id="imgAsset167" src="thmb168.swf" embedded="0"/>
		<graphicAsset id="imgAsset168" src="thmb169.swf" embedded="0"/>
		<graphicAsset id="imgAsset169" src="thmb170.swf" embedded="0"/>
		<graphicAsset id="imgAsset170" src="thmb171.swf" embedded="0"/>
		<graphicAsset id="imgAsset171" src="thmb172.swf" embedded="0"/>
		<graphicAsset id="imgAsset172" src="thmb173.swf" embedded="0"/>
		<graphicAsset id="imgAsset173" src="thmb174.swf" embedded="0"/>
		<graphicAsset id="imgAsset174" src="thmb175.swf" embedded="0"/>
		<graphicAsset id="imgAsset175" src="thmb176.swf" embedded="0"/>
		<graphicAsset id="imgAsset176" src="thmb177.swf" embedded="0"/>
		<graphicAsset id="imgAsset177" src="thmb178.swf" embedded="0"/>
		<graphicAsset id="imgAsset178" src="thmb179.swf" embedded="0"/>
		<graphicAsset id="imgAsset179" src="thmb180.swf" embedded="0"/>
		<graphicAsset id="imgAsset180" src="thmb181.swf" embedded="0"/>
		<graphicAsset id="imgAsset181" src="thmb182.swf" embedded="0"/>
		<graphicAsset id="imgAsset182" src="thmb183.swf" embedded="0"/>
		<graphicAsset id="imgAsset183" src="thmb184.swf" embedded="0"/>
		<graphicAsset id="imgAsset184" src="thmb185.swf" embedded="0"/>
		<graphicAsset id="imgAsset185" src="thmb186.swf" embedded="0"/>
		<graphicAsset id="imgAsset186" src="thmb187.swf" embedded="0"/>
		<graphicAsset id="imgAsset187" src="thmb188.swf" embedded="0"/>
		<graphicAsset id="imgAsset188" src="thmb189.swf" embedded="0"/>
		<graphicAsset id="imgAsset189" src="thmb190.swf" embedded="0"/>
		<graphicAsset id="imgAsset190" src="thmb191.swf" embedded="0"/>
		<graphicAsset id="imgAsset191" src="thmb192.swf" embedded="0"/>
		<graphicAsset id="imgAsset192" src="thmb193.swf" embedded="0"/>
	</graphicAssets>
	<playlists/>
	<narration/>
	<settings>
		<navigation>
			<keyboard enabled="1">
				<actions>
					<action name="playPause">
						<shortcut code="32" control="0" shift="0"/>
					</action>
					<action name="nextSlide">
						<shortcut code="34" control="0" shift="0"/>
					</action>
					<action name="previousSlide">
						<shortcut code="33" control="0" shift="0"/>
					</action>
					<action name="nextStep">
						<shortcut code="13" control="0" shift="0"/>
					</action>
					<action name="previousStep">
						<shortcut code="13" control="0" shift="1"/>
					</action>
					<action name="firstSlide">
						<shortcut code="36" control="1" shift="0"/>
					</action>
					<action name="lastSlide">
						<shortcut code="35" control="1" shift="0"/>
					</action>
					<action name="lastViewedSlide">
						<shortcut code="8" control="0" shift="0"/>
					</action>
					<action name="slideStart">
						<shortcut code="36" control="0" shift="0"/>
					</action>
					<action name="slideEnd">
						<shortcut code="35" control="0" shift="0"/>
					</action>
					<action name="seekForward">
						<shortcut code="39" control="0" shift="0"/>
					</action>
					<action name="seekBackward">
						<shortcut code="37" control="0" shift="0"/>
					</action>
					<action name="volumeUp">
						<shortcut code="38" control="0" shift="0"/>
					</action>
					<action name="volumeDown">
						<shortcut code="40" control="0" shift="0"/>
					</action>
					<action name="toggleFullscreen">
						<shortcut code="70" control="1" shift="0"/>
					</action>
				</actions>
			</keyboard>
			<mouse enabled="1" target="step"/>
			<gesture zoom="1"/>
		</navigation>
		<skin>
			<currentTemplate baseId="PRESENTATION"/>
			<colorSettings>
				<color id="button.content.normal">#FFFFFF</color>
				<color id="button.content.over">#FFFFFF</color>
				<color id="button.face.normal">#777777</color>
				<color id="button.face.over">#575757</color>
				<color id="companyLogo.background">#FFFFFF</color>
				<color id="hyperlink">#097CE7</color>
				<color id="listItem.face.over">#E8E8E8</color>
				<color id="listItem.face.pressed">#6E6E6E</color>
				<color id="listItem.label.over">#000000</color>
				<color id="listItem.label.pressed">#FFFFFF</color>
				<color id="listItem.label.visited">#A1A1A1</color>
				<color id="page.background">#8A8A8A</color>
				<color id="panel.background">#F7F7F7</color>
				<color id="panel.text">#323232</color>
				<color id="player.background">#D4D4D4</color>
				<color id="popup.background">#FFFFFF</color>
				<color id="progress.background">#6E6E6E</color>
				<color id="progress.loading">#D0D0D0</color>
				<color id="progress.playback">#A1A1A1</color>
				<color id="text">#4D4D4D</color>
			</colorSettings>
			<controlPanelSettings>
				<visible>true</visible>
				<showOutline>false</showOutline>
				<showPlayPause>true</showPlayPause>
				<showRewind>true</showRewind>
				<showVolumeControl>false</showVolumeControl>
				<showCCButton>false</showCCButton>
				<showPrevButton>true</showPrevButton>
				<showNextButton>true</showNextButton>
				<showSlideOnlyButton>true</showSlideOnlyButton>
				<progressBar>
					<visible>true</visible>
					<enabled>true</enabled>
					<showLabels>true</showLabels>
					<mode>slideTimeline</mode>
				</progressBar>
				<navigationMode>bySlides</navigationMode>
			</controlPanelSettings>
			<titlePanelSettings>
				<showLogo>false</showLogo>
				<visible>false</visible>
				<buttons>
					<button type="attachments" visible="false"/>
					<button type="presenterInfo" visible="false"/>
					<button type="markerTools" visible="false"/>
					<button type="notes" visible="false"/>
					<button type="outline" visible="false"/>
				</buttons>
			</titlePanelSettings>
			<outlinePanelSettings>
				<numberEntries>true</numberEntries>
				<highlightViewedEntries>false</highlightViewedEntries>
				<thumbnails>true</thumbnails>
				<search>true</search>
				<multilevel>false</multilevel>
			</outlinePanelSettings>
			<sidePanelSettings>
				<showAtLeft>false</showAtLeft>
				<showLogo>false</showLogo>
				<showPresenterInfo>false</showPresenterInfo>
				<showPresenterVideo>false</showPresenterVideo>
				<visible>true</visible>
				<tabsPanel>
					<showOutline>true</showOutline>
					<showNotes>false</showNotes>
				</tabsPanel>
			</sidePanelSettings>
		</skin>
		<appearance fullScreen="1" showSlidePreloader="1"/>
		<playback autoStart="1" syncWithVideoNarration="1" enableVideoControl="1" resumePresentationPlayback="never"/>
	</settings>
	<slides embedded="0">
		<slide index="0" title="Endocrine Treatment &amp; Endocrine Resistance in Breast Cancer" titleNormalized="endocrine treatment &amp; endocrine resistance in breast cancer" src="slide1.swf" size="23541" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>1</notes>
			<notesNormalized>1</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;1&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Endocrine Treatment &amp; Endocrine Resistance in Breast Cancer
Endocrine Physiology and Pharmacology
10th of November 2017
Dr Alexey Larionov</text>
		</slide>
		<slide index="1" title="" titleNormalized="" src="slide2.swf" size="6083" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset1">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>2</notes>
			<notesNormalized>2</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;2&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Discussing reading list
Endocrine treatment in breast cancer
Breast Cancer
Oestrogen Receptor

Endocrine treatment

Short group task
Endocrine resistance in breast cancer
Impact &amp; current management
Mechanisms of endocrine resistance
Future: biomarker-guided targeted treatment and monitoring
Plan of the seminar</text>
		</slide>
		<slide index="2" title="" titleNormalized="" src="slide3.swf" size="5371" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset2">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>4</notes>
			<notesNormalized>4</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;4&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Why I recommended these papers ?
Reading list discussion</text>
		</slide>
		<slide index="3" title="" titleNormalized="" src="slide4.swf" size="5372" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset3">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>5</notes>
			<notesNormalized>5</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;5&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>What was the most interesting paper ?
Reading list discussion</text>
		</slide>
		<slide index="4" title="" titleNormalized="" src="slide5.swf" size="34305" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset4">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>6</notes>
			<notesNormalized>6</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;6&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>What was the most interesting paper ?
Reading list discussion</text>
		</slide>
		<slide index="5" title="" titleNormalized="" src="slide6.swf" size="5443" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset5">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>7</notes>
			<notesNormalized>7</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;7&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>What this paper is about ?
Beatson (1896)

– For the first time suggests oophorectomy for treatment
 of beast cancer

– Reports two clinical cases of breast cancer with 
 very good clinical response to oophorectomy

– Illustrates the way of scientific thinking in Victorian times
Reading list discussion</text>
		</slide>
		<slide index="6" title="" titleNormalized="" src="slide7.swf" size="125037" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset6">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>8</notes>
			<notesNormalized>8</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;8&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Why I like this paper ?
Beatson (1896)

Reading list discussion</text>
		</slide>
		<slide index="7" title="" titleNormalized="" src="slide8.swf" size="61016" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset7">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>9</notes>
			<notesNormalized>9</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;9&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Why I like this paper ?
Beatson (1896)

Reading list discussion</text>
		</slide>
		<slide index="8" title="" titleNormalized="" src="slide9.swf" size="57912" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset8">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>10</notes>
			<notesNormalized>10</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;10&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Beatson’s initial idea was 
to convert breast cancer into milk 
by mean of oophorectomy

Why I like this paper ?
Beatson (1896)

Reading list discussion</text>
		</slide>
		<slide index="9" title="" titleNormalized="" src="slide10.swf" size="46878" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset9">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>11</notes>
			<notesNormalized>11</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;11&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Pre-vision of endocrine system !
Why I like this paper ?
Beatson (1896)

Reading list discussion</text>
		</slide>
		<slide index="10" title="" titleNormalized="" src="slide11.swf" size="37046" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset10">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>12</notes>
			<notesNormalized>12</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;12&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Main role of oestrogens 
in breast cancer!
Why I like this paper ?
Beatson (1896)

Reading list discussion</text>
		</slide>
		<slide index="11" title="" titleNormalized="" src="slide12.swf" size="66921" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset11">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>13</notes>
			<notesNormalized>13</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;13&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Why I like this paper ?
Beatson (1896)


Making a Unihorn ?!
Reading list discussion</text>
		</slide>
		<slide index="12" title="" titleNormalized="" src="slide13.swf" size="5269" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset12">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>14</notes>
			<notesNormalized>14</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;14&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Reading list discussion</text>
		</slide>
		<slide index="13" title="" titleNormalized="" src="slide14.swf" size="5535" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset13">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>15</notes>
			<notesNormalized>15</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;15&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Discussing reading list
Endocrine treatment in breast cancer
Breast Cancer
Oestrogen Receptor
Endocrine treatment
Short group task
Endocrine resistance in breast cancer
Impact &amp; current management
Mechanisms of endocrine resistance
Future: biomarker-guided targeted treatment and monitoring
Plan of the seminar</text>
		</slide>
		<slide index="14" title="" titleNormalized="" src="slide15.swf" size="5463" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset14">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>16</notes>
			<notesNormalized>16</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;16&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>World-wide
Most common female cancer: ~1.7M new cases each year

In the UK
~ 30% of female cancers
1 in 8 women will be affected in the life-time
~ 50,000 women are diagnosed with breast cancer each year ~ 12,000 women are dying of breast cancer each year
~ £1.5bn annual costs (£0.6bn health care + £0.9bn other costs)
Impact of Breast Cancer
Data for 2012-2014, from WCRF, Cancer Research UK and NCRI</text>
		</slide>
		<slide index="15" title="" titleNormalized="" src="slide16.swf" size="5539" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset15">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>16</notes>
			<notesNormalized>16</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;16&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>World-wide
Most common female cancer: ~1.7M new cases each year

In the UK
~ 30% of female cancers
1 in 8 women will be affected in the life-time
~ 50,000 women are diagnosed with breast cancer each year ~ 12,000 women are dying of breast cancer each year
~ £1.5bn annual costs (£0.6bn health care + £0.9bn other costs)
Data for 2012-2014, from WCRF, Cancer Research UK and NCRI
Impact of Breast Cancer</text>
		</slide>
		<slide index="16" title="" titleNormalized="" src="slide17.swf" size="25095" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset16">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>Outcome of Breast Cancer
Stage at diagnosis (% of patients, 3% unknown)
5-yrs survival 
(% of patients, depending on stage)
Modified from DeSantis et al: Breast Cancer Statistics, 2017 … (PMID 28972651)</text>
		</slide>
		<slide index="17" title="" titleNormalized="" src="slide18.swf" size="5608" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset17">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>17</notes>
			<notesNormalized>17</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;17&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Reproductive factors
High risk: increased exposure to oestrogens
Protective: pregnancy, breast feeding

Inheritance 
High penetrance genes (familial breast cancer, BRACA1/2, PALB2 etc.)
Low penetrance genes and multi-gene predisposition (may have no familial history)

Life style
Obesity (in post menopause only!)
Intake of saturated fat, alcohol, OC, HRT (RRs &lt;1.5) 
Breast Cancer Risk Factors</text>
		</slide>
		<slide index="18" title="" titleNormalized="" src="slide19.swf" size="5266" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset18">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>18</notes>
			<notesNormalized>18</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;18&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Breast Cancer: Relative Risks
1x
These are representative examples. Effects may vary between studies, breast cancer sub-types, selected thresholds etc.</text>
		</slide>
		<slide index="19" title="" titleNormalized="" src="slide20.swf" size="31203" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset19">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>19</notes>
			<notesNormalized>19</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;19&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>1x
Age-associated risk
Breast Cancer: Relative Risks</text>
		</slide>
		<slide index="20" title="" titleNormalized="" src="slide21.swf" size="5513" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset20">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>20</notes>
			<notesNormalized>20</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;20&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Smoking for lung cancer
A conservative estimate
These are representative examples. Effects may vary between studies, breast cancer sub-types, selected thresholds etc. 
Breast Cancer: Relative Risks</text>
		</slide>
		<slide index="21" title="" titleNormalized="" src="slide22.swf" size="44604" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset21">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>21</notes>
			<notesNormalized>21</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;21&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Pathology and biology of tumour
Pathology
- Ductal, Lobular, other rare types
- Invasive, In Situ 
Molecular markers (&amp; mechanisms)
- Oestrogen Receptor (ER)
- Progesterone Receptor (PgR, confirmatory to ER)
- Human Epidermal Growth Factor Receptor 2 (HER2)
- Others: Ki67, BRCA1/2 …
Breastcancer.org
Breast Cancer: Biological Diversity
Hormonal status of patient
- Pre / Peri / Post menopause</text>
		</slide>
		<slide index="22" title="" titleNormalized="" src="slide23.swf" size="6371" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset22">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>Current clinically relevant sub-groups
ER
+
+
-
-
PgR
+
+
-
-
HER2
-
+
+
-
Incidence per 100k
Luminal-A
Basal
Luminal-B
Alternative
designation
Modified from DeSantis et al: Breast Cancer Statistics, 2017 … (PMID 28972651) 
Breast Cancer: Biological Diversity</text>
		</slide>
		<slide index="23" title="" titleNormalized="" src="slide24.swf" size="87187" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset23">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>22</notes>
			<notesNormalized>22</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;22&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>A group of 5 several biologically distinctive cancers
Sørlie et al, PNAS, 2003, vol. 100, no. 14, 8418–8423 
Transcriptome (mRNA) molecular profiling
C.Perou and T.Sorlie confirmed main clinical sub-types identified previously
ER+ve HER2-ve
Triple Negative
HER2+ve
Equivalent
clinical groups:
Luminal B
Triple Negative
HER2+ve
Luminal A
Normal-like
5 groups:
Breast Cancer: Biological Diversity</text>
		</slide>
		<slide index="24" title="" titleNormalized="" src="slide25.swf" size="100927" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset24">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>22</notes>
			<notesNormalized>22</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;22&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Curtis et al 2012 PMID 22522925
Carlos Caldas suggests groups previously missed by currently used clinical markers …
Breast Cancer: Biological Diversity
A group of 10 several biologically distinctive cancers
Copy Number Variants (CNV) profiling</text>
		</slide>
		<slide index="25" title="" titleNormalized="" src="slide26.swf" size="135389" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset25">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>22</notes>
			<notesNormalized>22</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;22&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Whole Genome Sequencing (WGS)
individual mutational signatures
Nik-Zainal 2017 PMID 28572256
Distant rearrangements
(ER-ve)
INDELs
CNVs
Distant
rearrangements
Chromosomes
T&gt;C
C&gt;T
Low 
mutational burden
T&gt;C C&gt;T C&gt;A C&gt;G T&gt;A T&gt;G
SNVs
Breast Cancer: Biological Diversity</text>
		</slide>
		<slide index="26" title="" titleNormalized="" src="slide27.swf" size="56763" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset26">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>Wang Y et al 2014: Nature 512:155-60, PMID: 25079324
Example of a clonal evolution in breast cancer 
Breast Cancer: Intra-tumoral heterogeneity
Primary tumour
Regional Mts to lymph nodes
Distant Mts to different locations (bone, liver, lung, brain) 
Progression during the time</text>
		</slide>
		<slide index="27" title="" titleNormalized="" src="slide28.swf" size="10425" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset27">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>23</notes>
			<notesNormalized>23</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;23&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Surgery
Diagnosis
Dissemination
Early Breast Cancer
Local relapse
with or without axillary
lymph-node involvement
Advanced Breast Cancer
distant metastases or 
locally advanced
Breast Cancer: Clinical Diversity
Typical history of disease</text>
		</slide>
		<slide index="28" title="" titleNormalized="" src="slide29.swf" size="11142" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset28">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>24</notes>
			<notesNormalized>24</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;24&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Surgery
Diagnosis
Dissemination
Response (tumour size)
Response (size and spread)
Disease-Free Survival
3 -5+ yrs.
Overall Survival (5-10+ yrs.)
Adjuvant treatment
Neo-adjuvant treatment
(3+ months) 
Metastatic/advanced disease treatment 
Larionov &amp; Miller 2009 Future Oncology 5(9): 1415-1428
Treatment settings &amp; Response assessment
Breast Cancer: Clinical Diversity</text>
		</slide>
		<slide index="29" title="" titleNormalized="" src="slide30.swf" size="97013" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset29">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>21</notes>
			<notesNormalized>21</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;21&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Breastcancer.org
Surgery
Diagnosis
Dissemination



DIVERSITY



Breast Cancer Biology &amp; Clinical features</text>
		</slide>
		<slide index="30" title="" titleNormalized="" src="slide31.swf" size="5356" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset30">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>25</notes>
			<notesNormalized>25</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;25&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Surgery
X-ray
Cytotoxic Chemotherapy 
e.g. Anthracyclines , Taxanes, Antimetabolites , DNA-cross-linking agents etc.
Endocrine Therapy
e.g. Aromatase Inhibitors or Tamoxifen for ER-positive tumours
Targeted Therapy
e.g. Herceptin for tumours with HER2 amplification, CDK4/6 inhibitors etc
Other Treatments
e.g. pain control, immune-therapy etc.
Breast Cancer: Treatment Methods</text>
		</slide>
		<slide index="31" title="" titleNormalized="" src="slide32.swf" size="5488" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset31">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>26</notes>
			<notesNormalized>26</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;26&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Surgery
X-ray
Cytotoxic Chemotherapy 
e.g. Anthracyclines , Taxanes, Antimetabolites , DNA-cross-linking agents etc.
Endocrine Therapy
e.g. Aromatase Inhibitors or Tamoxifen for ER-positive tumours
Targeted Therapy
e.g. Herceptin for tumours with HER2 amplification, CDK4/6 inhibitors etc
Other Treatments
e.g. pain control, immune-therapy etc.
Breast Cancer: Treatment Methods</text>
		</slide>
		<slide index="32" title="" titleNormalized="" src="slide33.swf" size="4834" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset32">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>27</notes>
			<notesNormalized>27</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;27&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Normal breast is oestrogen-dependent
Endocrine Treatment: Biological Rationale</text>
		</slide>
		<slide index="33" title="" titleNormalized="" src="slide34.swf" size="6145" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset33">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>27</notes>
			<notesNormalized>27</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;27&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Normal breast is oestrogen-dependent
Embryonal: morphogenesis begins in utero, pauses between birth and puberty
Puberty: Eg support ductal branching, Pg support initial lobular development
Pregnancy: both Eg and Pg are needed for full development of terminal regions
What does it mean? 
Effect of oestrogens on breast development
Effect of oestrogens on breast during the cycle
Oestrogen effects on breast in post-menopause
Overall: Sufficient evidence supports proliferative effect of Eg and Pg in breast.
However, ERs are decreased and mitotic rates are increased in luteal phase …
Complicated by technicalities of measuring fluctuating levels of Eg …
Oestrogen blood level drops in post-menopause.
Local levels of oestrogens in breast often are significantly above the blood levels …
HRT studies show that oestrogen may be protective of BC …
Endocrine Treatment: Biological Rationale</text>
		</slide>
		<slide index="34" title="" titleNormalized="" src="slide35.swf" size="204752" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset34">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>Role of hormones in ductal branching and lobular development
Ductal (ER+/-)
Stem cells → Progenitors → Mature epithelial cells
Luminal (ER-)
Myoepithelial (ER-)
Ducts
bi-layered epithelium
Myoepithelium + 
Luminal cells
Adipocytes
Fibroblasts
Terminal buds
(future alveoli)
Easy to access and
experiment
Breast development in mice
Visvader et al 2014 : PMID 24888586, Fu et al 2014 : PMID: 24439805</text>
		</slide>
		<slide index="35" title="" titleNormalized="" src="slide36.swf" size="62122" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset35">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>28</notes>
			<notesNormalized>28</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;28&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Effect of oestrogens on human breast development ?
Not much more studies done on human lactating breast …
Girls lacking aromatase do not develop breasts during puberty, which 
is corrected by oestrogen replacement. (Simpson 2015, PMID 26438567 )
However, these experiments are rare: 
Nature makes experiments on humans: 
Gusterson 2012: Human breast development (Review, PMID: 22426022 )
How would you study normal human breast development?</text>
		</slide>
		<slide index="36" title="" titleNormalized="" src="slide37.swf" size="14000" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset36">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>Note: This slide shows selected results only. Effect of contraceptives on BC depends on many factors, including type and dose of steroids, way of administration (oral or injectable), age, duration of use, time since use and others. OCs have many effects beside the BC. For instance, OCs may be protective of endometrial and ovarian cancers (Grevers 2016, PMID 28018891; Iversen 2017, PMID 28188769). 
Effect of oestrogens on human breast during the cycle ?
Beaber 2014, PMID 25085875 (Table 6, Monophasic Combined OC) Moderate Eg = 30–35 mg ethinyl estradiol, Low Eg = 20 mg ethinyl estradiol
BC risk (relatively to never users)
A large human-made “experiment” : oral contraceptives
A study on 20k+ cases and controls (USA)</text>
		</slide>
		<slide index="37" title="" titleNormalized="" src="slide38.swf" size="20242" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset37">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>Interaction with progesterone
? Progestin is good - Oestrogen is bad ?
Samson 2017, PMID 27889052
Kumle 2002, PMID 12433714 
Hazard Ratio of death from BC
(relatively to never users)
A study from South Carolina, US 
~5k BC cases
Swedish Women’s Lifestyle and Health Cohort
100k + participants
BC risk (relatively to never users)
Note: This slide shows selected results only. Effect of contraceptives on BC depends on many factors, including type and dose of steroids, way of administration (oral or injectable), age, duration of use, time since use and others. OCs have many effects beside the BC. For instance, OCs may be protective of endometrial and ovarian cancers (Grevers 2016, PMID 28018891; Iversen 2017, PMID 28188769). 
Effect of oestrogens on human breast during the cycle ?</text>
		</slide>
		<slide index="38" title="" titleNormalized="" src="slide39.swf" size="13963" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset38">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>Note: This slide shows selected results only. Effect of HRT is not just about progestins, it is also depends on duration of menopause, type of steroids etc (Santen 2010, PMID 20566620)
Women's Health Initiative study: 16k+ participants (USA)
Anderson 2004, PMID 15082697
(Rossouw 2002, PMID 12117397)
participants after hysterectomy
More large human “experiments”: Hormone Replacement Therapy
Effect of oestrogens on human breast in post-menopause?
? Progestin is bad - Oestrogen is good !?</text>
		</slide>
		<slide index="39" title="" titleNormalized="" src="slide40.swf" size="22413" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset39">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>Note: This slide shows selected results only. Effect of HRT is not just about progestins, it is also depends on duration of menopause, type of steroids etc (Santen 2010, PMID 20566620)
Anderson 2004, PMID 15082697
(Rossouw 2002, PMID 12117397)
participants after hysterectomy
Effect of oestrogens on human breast in post-menopause?


Oestrogen-induced apoptosis 
in post-menopause ?
Can oestrogen protect from breast cancer ? !!!</text>
		</slide>
		<slide index="40" title="" titleNormalized="" src="slide41.swf" size="5697" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset40">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>27</notes>
			<notesNormalized>27</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;27&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Effect of oestrogens on breast in puberty and during pregnancy
Effect of oestrogens on breast during the cycle
Oestrogen effects on breast in post-menopause
Little data
Plenty of 
interesting but confusing data
Normal human breast is oestrogen-dependent
Endocrine Treatment: Biological Rationale</text>
		</slide>
		<slide index="41" title="" titleNormalized="" src="slide42.swf" size="5570" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset41">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>29</notes>
			<notesNormalized>29</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;29&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Fact:
Oestrogens stimulate breast (ductal tree) development
Many facts about normal breast are derived from animal models …
(We know much more about rats’ breasts than about humans’ …)
Yet to be studied:
How oestrogens stimulate proliferation and apoptosis in normal breast?
How oestrogens act on breast in different periods of life?
Endocrine Treatment: Biological Rationale
Normal human breast is oestrogen-dependent</text>
		</slide>
		<slide index="42" title="" titleNormalized="" src="slide43.swf" size="5186" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset42">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>30</notes>
			<notesNormalized>30</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;30&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Reduction of oestrogens may cause involution
of ER-positive breast cancers
Empirical ?
60-70% of breast cancers express ERs
Endocrine Treatment: Biological Rationale</text>
		</slide>
		<slide index="43" title="" titleNormalized="" src="slide44.swf" size="5541" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset43">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>31</notes>
			<notesNormalized>31</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;31&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Discussing reading list
Endocrine treatment in breast cancer
Breast Cancer
Oestrogen Receptor
Endocrine treatment
Short group task
Endocrine resistance in breast cancer
Impact &amp; current management
Mechanisms of endocrine resistance
Future: biomarker-guided targeted treatment and monitoring
Plan of the seminar</text>
		</slide>
		<slide index="44" title="" titleNormalized="" src="slide45.swf" size="5246" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset44">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>71</notes>
			<notesNormalized>71</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;71&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Endocrine treatment is NOT effective in any Oestrogen Receptor negative (ER-ve) tumours 
Oestrogen receptor is
Endocrine treatment is effective in most (~70%) 
of Oestrogen Receptor positive (ER+ve) tumours
Endocrine treatment is indicated to
Oestrogen Receptor positive tumours ONLY
the main biomarker for endocrine treatment</text>
		</slide>
		<slide index="45" title="" titleNormalized="" src="slide46.swf" size="12455" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset45">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>32</notes>
			<notesNormalized>32</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;32&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Oestrogen receptors and effects
ER
beta
DNA
AP1
DNA
DNA
Nucleus
Cytoplasm
Plasma membrane
associated ER
Plasma membrane
Intra-cellular
membranes
GPER
Genomic effects, mediated by changes in genes transcription
and synthesis of new proteins (hours and days)
Signalling through 
secondary messengers 
and kinase cascades
Rapid effects
(minutes)
ER
alpha
Prossnitz &amp; Barton 2011 Nature Reviews Endocrinology 7, 715; Weatherman 2006 Nature Chemical Biology 2, 175 etc</text>
		</slide>
		<slide index="46" title="" titleNormalized="" src="slide47.swf" size="13269" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset46">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>33</notes>
			<notesNormalized>33</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;33&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>ER
beta
AP1
DNA
DNA
Nucleus
Cytoplasm
Plasma membrane
associated ER
Plasma membrane
Intra-cellular
membranes
GPER
Canonical signalling through ER-alpha is 
yet the most studied in BC (2017)
Signalling through 
secondary messengers 
and kinase cascades
Rapid effects
(minutes)
ER
alpha
DNA
Prossnitz &amp; Barton 2011 Nature Reviews Endocrinology 7, 715; Weatherman 2006 Nature Chemical Biology 2, 175 etc
Oestrogen receptors and effects</text>
		</slide>
		<slide index="47" title="" titleNormalized="" src="slide48.swf" size="7331" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset47">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>34</notes>
			<notesNormalized>34</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;34&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Hinge
NTD (AF1)
DBD
LBD(AF2)
N
C
Domain structure of ER-alpha
C-terminal helix (H12)
DBD – DNA- binding domain
NTD – N-terminal domain
LBD – Ligand-binding domain
(binds to oestrogen)
AF1/2 – Activating functions 1 / 2 (historical designation for parts 
of NTD and LBD interacting with 
Nuclear co-activators)
NTD
(AF1)
LBD
(AF2)
DBD</text>
		</slide>
		<slide index="48" title="" titleNormalized="" src="slide49.swf" size="6699" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset48">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>35</notes>
			<notesNormalized>35</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;35&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Inactive ER-alpha without ligand
Nuclear factor located in cytoplasm (?)
bound to a chaperon protein
Heat-Shock Protein 90
NTD
(AF1)
LBD
(AF2)
DBD
HSP90
NTD
(AF1)
LBD
(AF2)
DBD
HSP90</text>
		</slide>
		<slide index="49" title="" titleNormalized="" src="slide50.swf" size="11698" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset49">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>36</notes>
			<notesNormalized>36</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;36&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Signalling through ER-alpha (1)
NTD
(AF1)
LBD
(AF2)
DBD
HSP90
NTD
(AF1)
LBD
(AF2)
DBD
HSP90
Cytoplasm ?
Nucleus
E2
E2
Ligand binding, HSP90 release
(trans) location into nucleus</text>
		</slide>
		<slide index="50" title="" titleNormalized="" src="slide51.swf" size="7566" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset50">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>37</notes>
			<notesNormalized>37</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;37&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Signalling through ER-alpha (2)
NTD
(AF1)
LBD
(AF2)
DBD
NTD
(AF1)
LBD
(AF2)
DBD
E2
E2
Phosphorylation, Dimerization
P
P</text>
		</slide>
		<slide index="51" title="" titleNormalized="" src="slide52.swf" size="10552" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset51">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>38</notes>
			<notesNormalized>38</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;38&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Signalling through ER-alpha (3)
NTD
(AF1)
LBD
(AF2)
DBD
E2
NTD
(AF1)
LBD
(AF2)
DBD
E2
Binding to DNA on Oestrogen Responsive Elements (ERE)
5’-aGGTCA-nnn-TGACCt-3’
Palindromic sequence (may slightly vary)
Klinge, NAR, 2001, 29(14):2905
P
P
ERE</text>
		</slide>
		<slide index="52" title="" titleNormalized="" src="slide53.swf" size="10368" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset52">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>39</notes>
			<notesNormalized>39</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;39&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Signalling through ER-alpha (4)
NTD
(AF1)
LBD
(AF2)
DBD
E2
NTD
(AF1)
LBD
(AF2)
DBD
E2
Binding to DNA on Oestrogen Responsive Elements (ERE)
5’-aGGTCA-nnn-TGACCt-3’
Palindromic sequence (may slightly vary)
Klinge, NAR, 2001, 29(14):2905
P
P
Availability of specific ERE is tissue-specific
Local chromatin structure depends on
Pioneering factors 
FOXA1 and GATA3
Epigenetics marks
e.g. CpG methylation, histones modification
Activity of enhancers
…
ERE
GATA3
FOXA1</text>
		</slide>
		<slide index="53" title="" titleNormalized="" src="slide54.swf" size="11369" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset53">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>40</notes>
			<notesNormalized>40</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;40&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Signalling through ER-alpha (5)
Transcription initiation complex (RNA-polymerase-II etc.)
Transcription initiation in cooperation with AF1-dependent nuclear co-activators
(tissue-specific: uterus, bones?)
AF1-dependent
Co-activators

NTD
(AF1)
LBD
(AF2)
DBD
E2
NTD
(AF1)
LBD
(AF2)
DBD
E2
P
P
GATA3
FOXA1</text>
		</slide>
		<slide index="54" title="" titleNormalized="" src="slide55.swf" size="11459" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset54">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>41</notes>
			<notesNormalized>41</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;41&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Signalling through ER-alpha (6)
Transcription initiation in cooperation with AF2-dependent nuclear co-activators
(tissue-specific, including breast epithelium)
Transcription initiation complex (RNA-polymerase-II etc.)
AF2-dependent
Co-activator
NTD
(AF1)
LBD
(AF2)
DBD
E2
NTD
(AF1)
LBD
(AF2)
DBD
E2
P
P
GATA3
FOXA1</text>
		</slide>
		<slide index="55" title="" titleNormalized="" src="slide56.swf" size="9876" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset55">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>42</notes>
			<notesNormalized>42</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;42&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>NTD
(AF1)
LBD
(AF2)
DBD
NTD
(AF1)
LBD
(AF2)
DBD
P
P
DNA
(ERE)
LBD
E2
DBD
DNA-bound ER-alpha
3D computer modelling based on X-ray crystallography
E2
E2
D.Goodsell , PDB: Molecule of the Month, September 2003
GATA3
FOXA1</text>
		</slide>
		<slide index="56" title="" titleNormalized="" src="slide57.swf" size="10190" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset56">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>43</notes>
			<notesNormalized>43</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;43&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>NTD
(AF1)
LBD
(AF2)
DBD
NTD
(AF1)
LBD
(AF2)
DBD
P
P
DNA
(ERE)
LBD
E2
DBD
3D computer modelling based on X-ray crystallography
E2
E2
D.Goodsell , PDB: Molecule of the Month, September 2003
Artificial position
of H12
GATA3
FOXA1
DNA-bound ER-alpha</text>
		</slide>
		<slide index="57" title="" titleNormalized="" src="slide58.swf" size="267935" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset57">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>44</notes>
			<notesNormalized>44</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;44&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>DNA
(ERE)
DBD
PDB: 1HCQ
Schwabe et al, Cell, 1993, 75: 567-578 
3D computer modelling based on X-ray crystallography
Dimerized DNA-Binding Domain attached to ERE</text>
		</slide>
		<slide index="58" title="" titleNormalized="" src="slide59.swf" size="275510" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset58">
			<sounds/>
			<videos/>
			<transitionEffect name="FadeSmoothly" duration="0.7000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>45</notes>
			<notesNormalized>45</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;45&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>DNA
(ERE)
DBD
PDB: 1HCQ
Schwabe et al, Cell, 1993, 75: 567-578 
3D computer modelling based on X-ray crystallography
Dimerized DNA-Binding Domain attached to ERE</text>
		</slide>
		<slide index="59" title="" titleNormalized="" src="slide60.swf" size="326198" advanceOnTime="0" framesCount="384" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset59">
			<sounds/>
			<videos>
				<video id="video0" videoClipId="ispring.resources_255500b0.spr0_183261940" slides="0" repeat="1" volume="0.8000000" posterFrameId="ispring.resources_255500b0.spr2_183261940" playFullScreen="0" hideWhenNotPlaying="0" rewindAfterPlaying="0"/>
			</videos>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands>
				<playVideo frameIndex="0" videoId="video0" startPos="0.0000000"/>
			</videoCommands>
			<animationSteps>
				<step start="0" end="383" playTime="15.9583333" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>46</notes>
			<notesNormalized>46</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;46&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>DNA
(ERE)
DBD
PDB: 1HCQ
Schwabe et al, Cell, 1993, 75: 567-578 
3D computer modelling based on X-ray crystallography
Dimerized DNA-Binding Domain attached to ERE</text>
		</slide>
		<slide index="60" title="" titleNormalized="" src="slide61.swf" size="259710" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset60">
			<sounds/>
			<videos/>
			<transitionEffect name="FadeSmoothly" duration="0.7000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>47</notes>
			<notesNormalized>47</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;47&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Dimerized Ligand-Binding Domain with E2
LBD
E2
PDB: 1A52
Tanenbaum et al, PNAS, 1998, 95: 5998-6003
3D computer modelling based on X-ray crystallography</text>
		</slide>
		<slide index="61" title="" titleNormalized="" src="slide62.swf" size="238149" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset61">
			<sounds/>
			<videos/>
			<transitionEffect name="FadeSmoothly" duration="0.7000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>48</notes>
			<notesNormalized>48</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;48&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>LBD
E2
PDB: 1A52
Tanenbaum et al, PNAS, 1998, 95: 5998-6003
3D computer modelling based on X-ray crystallography
Dimerized Ligand-Binding Domain with E2</text>
		</slide>
		<slide index="62" title="" titleNormalized="" src="slide63.swf" size="5789" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset62">
			<sounds/>
			<videos/>
			<transitionEffect name="FadeSmoothly" duration="0.7000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>50</notes>
			<notesNormalized>50</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;50&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Helix 12 in ER-alpha
LBD bound to Oestradiol : PDB 1A52
H12
Tanenbaum et al, PNAS, 1998, 95: 5998-6003
3D computer modelling based on X-ray crystallography
E2</text>
		</slide>
		<slide index="63" title="" titleNormalized="" src="slide64.swf" size="106145" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset63">
			<sounds/>
			<videos/>
			<transitionEffect name="FadeSmoothly" duration="0.7000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>51</notes>
			<notesNormalized>51</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;51&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>H12
Gangloff M, J Biol Chem. 2001, 276:15059-65
LBD bound to Oestradiol : PDB 1A52
LBD bound to Oestradiol : PDB 1QKU
Tanenbaum et al, PNAS, 1998, 95: 5998-6003
Artificial position of Helix 12
could be expected in ER w/o E2 ?
True position of Helix 12 after binding with E2
H12 closes the ligand binding pocket like a lid
Position of Helix 12 is flexible
E2
Helix 12 in ER-alpha</text>
		</slide>
		<slide index="64" title="" titleNormalized="" src="slide65.swf" size="218334" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset64">
			<sounds/>
			<videos/>
			<transitionEffect name="FadeSmoothly" duration="0.7000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>52</notes>
			<notesNormalized>52</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;52&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Gangloff M, J Biol Chem. 2001, 276:15059-65
LBD bound to Oestradiol : PDB 1A52
LBD bound to Oestradiol : PDB 1QKU
Tanenbaum et al, PNAS, 1998, 95: 5998-6003
Artificial position of Helix 12
could be expected in ER w/o E2 ?
True position of Helix 12 after binding with E2
H12 closes the ligand binding pocket like a lid
Position of Helix 12 is flexible
Helix 12 in ER-alpha</text>
		</slide>
		<slide index="65" title="" titleNormalized="" src="slide66.swf" size="5732" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset65">
			<sounds/>
			<videos/>
			<transitionEffect name="FadeSmoothly" duration="0.7000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>53</notes>
			<notesNormalized>53</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;53&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Gangloff M, J Biol Chem. 2001, 276:15059-65
LBD bound to Oestradiol : PDB 1A52
LBD bound to Oestradiol : PDB 1QKU
Tanenbaum et al, PNAS, 1998, 95: 5998-6003
Artificial position of Helix 12
could be expected in ER w/o E2 ?
True position of Helix 12 after binding with E2
H12 closes the ligand binding pocket like a lid
Position of Helix 12 is flexible
Helix 12 in ER-alpha</text>
		</slide>
		<slide index="66" title="" titleNormalized="" src="slide67.swf" size="6123" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset66">
			<sounds/>
			<videos/>
			<transitionEffect name="FadeSmoothly" duration="0.7000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>54</notes>
			<notesNormalized>54</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;54&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Gangloff M, J Biol Chem. 2001, 276:15059-65
LBD bound to Oestradiol : PDB 1A52
LBD bound to Oestradiol : PDB 1QKU
Tanenbaum et al, PNAS, 1998, 95: 5998-6003
Artificial position of Helix 12
could be expected in ER w/o E2 ?
True position of Helix 12 after binding with E2
H12 closes the ligand binding pocket like a lid
Position of Helix 12 is flexible
Helix 12 in ER-alpha</text>
		</slide>
		<slide index="67" title="" titleNormalized="" src="slide68.swf" size="57292" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset67">
			<sounds/>
			<videos/>
			<transitionEffect name="FadeSmoothly" duration="0.7000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>55</notes>
			<notesNormalized>55</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;55&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Gangloff M, J Biol Chem. 2001, 276:15059-65
LBD bound to Oestradiol : PDB 1A52
LBD bound to Oestradiol : PDB 1QKU
Tanenbaum et al, PNAS, 1998, 95: 5998-6003
Artificial position of Helix 12
could be expected in ER w/o E2 ?
True position of Helix 12 after binding with E2
H12 closes the ligand binding pocket like a lid
Position of Helix 12 is flexible
Helix 12 in ER-alpha</text>
		</slide>
		<slide index="68" title="" titleNormalized="" src="slide69.swf" size="95808" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset68">
			<sounds/>
			<videos/>
			<transitionEffect name="FadeSmoothly" duration="0.7000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>56</notes>
			<notesNormalized>56</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;56&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Effect of Tamoxifen on ER-alpha conformation
Tamoxifen protrudes from the ligand binding pocket and displaces H12
LBD bound to Oestradiol : PDB 1QKU
Gangloff M, J Biol Chem. 2001, 276:15059-65
Shiau et al, Cell. 1998 95:927-37
LBD bound to Tamoxifen : PDB 3ERT 
Oestradiol 
Tamoxifen</text>
		</slide>
		<slide index="69" title="" titleNormalized="" src="slide70.swf" size="184503" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset69">
			<sounds/>
			<videos/>
			<transitionEffect name="FadeSmoothly" duration="0.7000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>57</notes>
			<notesNormalized>57</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;57&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>LBD bound to Oestradiol : PDB 1QKU
Gangloff M, J Biol Chem. 2001, 276:15059-65
Shiau et al, Cell. 1998 95:927-37
LBD bound to Tamoxifen : PDB 3ERT 
Oestradiol 
Tamoxifen
Tamoxifen protrudes from the ligand binding pocket and displaces H12
Effect of Tamoxifen on ER-alpha conformation</text>
		</slide>
		<slide index="70" title="" titleNormalized="" src="slide71.swf" size="217785" advanceOnTime="0" framesCount="384" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset70">
			<sounds/>
			<videos>
				<video id="video1" videoClipId="ispring.resources_3c389db8.spr0_183266885" slides="1" repeat="1" volume="0.8000000" posterFrameId="ispring.resources_3c389db8.spr2_183266885" playFullScreen="0" hideWhenNotPlaying="0" rewindAfterPlaying="0"/>
				<video id="video2" videoClipId="ispring.resources_3c38a738.spr0_183267743" slides="1" repeat="1" volume="0.8000000" posterFrameId="ispring.resources_3c38a738.spr2_183267743" playFullScreen="0" hideWhenNotPlaying="0" rewindAfterPlaying="0"/>
			</videos>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands>
				<playVideo frameIndex="0" videoId="video1" startPos="0.0000000"/>
				<playVideo frameIndex="0" videoId="video2" startPos="0.0000000"/>
			</videoCommands>
			<animationSteps>
				<step start="0" end="383" playTime="15.9583333" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>58</notes>
			<notesNormalized>58</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;58&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>LBD bound to Oestradiol : PDB 1QKU
Gangloff M, J Biol Chem. 2001, 276:15059-65
Shiau et al, Cell. 1998 95:927-37
LBD bound to Tamoxifen : PDB 3ERT 
Oestradiol 
Tamoxifen
Tamoxifen protrudes from the ligand binding pocket and displaces H12
Effect of Tamoxifen on ER-alpha conformation</text>
		</slide>
		<slide index="71" title="" titleNormalized="" src="slide72.swf" size="11547" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset71">
			<sounds/>
			<videos/>
			<transitionEffect name="FadeSmoothly" duration="0.7000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>59</notes>
			<notesNormalized>59</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;59&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Transcription initiation complex (RNA-polymerase-II etc.)
AF2-dependent
Co-activator
NTD
(AF1)
LBD
(AF2)
DBD
NTD
(AF1)
LBD
(AF2)
DBD
P
P
E2
E2
GATA3
FOXA1
Terminology based on Johnston, Breast Cancer Research, 2005(7):119 
In breast ER drives expression of “type 2” genes using AF2-dependent co-activators
Tamoxifen action is different in different tissues</text>
		</slide>
		<slide index="72" title="" titleNormalized="" src="slide73.swf" size="12194" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset72">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>60</notes>
			<notesNormalized>60</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;60&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>AF2-dependent
Co-activator
Tamoxifen acts as oestrogen antagonist
NTD
(AF1)
LBD
(AF2)
DBD
NTD
(AF1)
LBD
(AF2)
DBD
TAM
P
P
TAM
Terminology based on Johnston, Breast Cancer Research, 2005(7):119 
GATA3
FOXA1
Transcription initiation complex (RNA-polymerase-II etc.)
In breast ER drives expression of “type 2” genes using AF2-dependent co-activators
Tamoxifen action is different in different tissues</text>
		</slide>
		<slide index="73" title="" titleNormalized="" src="slide74.swf" size="11993" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset73">
			<sounds/>
			<videos/>
			<transitionEffect name="FadeSmoothly" duration="0.7000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>61</notes>
			<notesNormalized>61</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;61&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>NTD
(AF1)
LBD
(AF2)
DBD
LBD
(AF2)
DBD
P
Transcription initiation complex (RNA-polymerase-II etc.)
TAM
TAM
AF1-dependent
Co-activators

Not a pure ani-oestrogen, but SERM 
Selective oEstrogen Receptor Modulator
GATA3
FOXA1
Terminology based on Johnston, Breast Cancer Research, 2005(7):119 
Tamoxifen acts as oestrogen agonist
In bone and uterus ER drives “type 1” genes using AF1-dependent co-activators
NTD
(AF1)
P
Tamoxifen action is different in different tissues</text>
		</slide>
		<slide index="74" title="" titleNormalized="" src="slide75.swf" size="5911" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset74">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>64</notes>
			<notesNormalized>64</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;64&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Discussing reading list
Endocrine treatment in breast cancer
Breast Cancer
Oestrogen Receptor

Endocrine treatment
Short group task
Endocrine resistance in breast cancer
Impact &amp; current management
Mechanisms of endocrine resistance
Future: biomarker-guided targeted treatment and monitoring
Plan of the seminar</text>
		</slide>
		<slide index="75" title="" titleNormalized="" src="slide76.swf" size="5539" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset75">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>65</notes>
			<notesNormalized>65</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;65&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Discussing reading list
Endocrine treatment in breast cancer
Breast Cancer
Oestrogen Receptor
Endocrine treatment
Short group task
Endocrine resistance in breast cancer
Impact &amp; current management
Mechanisms of endocrine resistance
Future: biomarker-guided targeted treatment and monitoring
Plan of the seminar</text>
		</slide>
		<slide index="76" title="" titleNormalized="" src="slide77.swf" size="15627" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset76">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>66</notes>
			<notesNormalized>66</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;66&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Ovary
(pre-menopause)
Peripheral tissues
(post-menopause)
Breast Cancer Cell
Oestrogen Receptor
Anti-oestrogens
Tamoxifen
Fulvestrant
Aromatase Inhibitors
Letrozole
Anastrozole
Exemestane
Ovarian suppression
Oophorectomy
GnRH agonists (Goserelin)
Larionov &amp; Miller, Treatment strategies, 2010
Endocrine treatment in breast cancer
Summary of currently available options</text>
		</slide>
		<slide index="77" title="" titleNormalized="" src="slide78.swf" size="29049" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset77">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>67</notes>
			<notesNormalized>67</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;67&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Ovary
(pre-menopause)
Peripheral tissues
(post-menopause)
Breast Cancer Cell
Oestrogen Receptor
Anti-oestrogens
Tamoxifen
Fulvestrant
Aromatase Inhibitors
Letrozole
Anastrozole
Exemestane
Ovarian suppression
Oophorectomy
GnRH agonists (Goserelin)
Larionov &amp; Miller, Treatment strategies, 2010
Endocrine treatment in breast cancer</text>
		</slide>
		<slide index="78" title="" titleNormalized="" src="slide79.swf" size="5861" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset78">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>68</notes>
			<notesNormalized>68</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;68&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Tamoxifen efficacy in Breast cancer
&amp; much less toxicity:
DES often caused nausea, oedema, vaginal bleeding, cardiac problems
Advanced Breast Cancer
Peethambaram et al, 1999, Breast Cancer Research and Treatment 54: 117–122
Tamoxifen vs. high doses of oestrogen
years
(DES = diethylstilboestrol)
Tamoxifen shows marginally less efficacy than high-dose oestrogen? 
(patients enrolled in 1977-1980)</text>
		</slide>
		<slide index="79" title="" titleNormalized="" src="slide80.swf" size="6038" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset79">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>69</notes>
			<notesNormalized>69</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;69&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>&amp; much less toxicity:
DES often caused nausea, oedema, vaginal bleeding, cardiac problems
Advanced Breast Cancer
Tamoxifen vs. high doses of oestrogen
years
(DES = diethylstilboestrol)
Peethambaram et al, 1999, Breast Cancer Research and Treatment 54: 117–122
(patients enrolled in 1977-1980)
Oestrogen Receptors UNKNOWN
Tamoxifen shows marginally less efficacy than high-dose oestrogen? 
Tamoxifen efficacy in Breast cancer</text>
		</slide>
		<slide index="80" title="" titleNormalized="" src="slide81.swf" size="66694" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset80">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>70</notes>
			<notesNormalized>70</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;70&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Advanced Breast Cancer
Tamoxifen efficacy in Breast cancer</text>
		</slide>
		<slide index="81" title="" titleNormalized="" src="slide82.swf" size="35161" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset81">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>72</notes>
			<notesNormalized>72</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;72&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Early Breast Cancer Trialists' Collaborative Group, Lancet, 1998, 351(9114): 1451
Early Breast Cancer
Adjuvant 
(post-operative)
treatment
Oestrogen Receptor 
positive cancers
Tamoxifen is more effective than no tamoxifen
Tamoxifen efficacy in Breast cancer</text>
		</slide>
		<slide index="82" title="" titleNormalized="" src="slide83.swf" size="37261" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset82">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>73</notes>
			<notesNormalized>73</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;73&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Early Breast Cancer Trialists' Collaborative Group, Lancet, 1998, 351(9114): 1451
Early Breast Cancer
Adjuvant 
(post-operative)
treatment
Tamoxifen is more effective than no tamoxifen
Tamoxifen efficacy in Breast cancer
Oestrogen Receptor 
positive cancers</text>
		</slide>
		<slide index="83" title="" titleNormalized="" src="slide84.swf" size="44114" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset83">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>74</notes>
			<notesNormalized>74</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;74&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Rationally designed in attempt to make an anti-oestrogen superior to Tamoxifen
“tamoxifen-like”
Droloxifene
Idoxifene
etc.
“fixed ring”
Arzoxifene
Acolbifene
etc.
SERMs of 1980s
Selective Oestrogen Receptor Modulators</text>
		</slide>
		<slide index="84" title="" titleNormalized="" src="slide85.swf" size="9896" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset84">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>75</notes>
			<notesNormalized>75</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;75&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Tissue
Effect of oestrogens
Tamoxifen
Toremifene
Raloxifene
Breast
Proliferation
Carcinogenesis
Antagonist
Antagonist
Antagonist
Uterus
Proliferation
Carcinogenesis
Agonist
Agonist
Not an agonist
Bones
Preserve bone density
Agonist
Agonist
Agonist
Clinical efficacy 
Based on: Johnston, Breast Cancer Research, 2005(7):119 
No superiority over Tamoxifen
Tissue-specific effects 
Not used widely for breast cancer treatment
SERMs of 1980s</text>
		</slide>
		<slide index="85" title="" titleNormalized="" src="slide86.swf" size="39811" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset85">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>76</notes>
			<notesNormalized>76</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;76&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Fulvestrant (Faslodex)
“Pure anti-oestrogen” : no estrogenic activity at all
“Oestrogen” with added bulk side chain
Faslodex with rat’s LBD (PDB 1HJ1) 
(H12 is hot shown…)
Tamoxifen with human LBD
(for comparison, PDB 3ERT)</text>
		</slide>
		<slide index="86" title="" titleNormalized="" src="slide87.swf" size="14248" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset86">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>77</notes>
			<notesNormalized>77</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;77&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Selective oEstrogen Receptor Degrader (SERD)
Binds to ER → Prevents ER dimerization → Triggers ER degradation
Good efficiency and poor bioavailability
Intramuscular: 500mg in 5-10 ml, monthly
Development was slowed down because the initial trials started at 250mg
Superiority over Tamoxifen/ AIs has became evident @ 500mg only …
“Oestrogen” with added bulk side chain
Clinical features
Mechanism
“Pure anti-oestrogen” : no estrogenic activity at all
Fulvestrant (Faslodex)</text>
		</slide>
		<slide index="87" title="" titleNormalized="" src="slide88.swf" size="29083" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset87">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>79</notes>
			<notesNormalized>79</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;79&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Ovary
(pre-menopause)
Peripheral tissues
(post-menopause)
Breast Cancer Cell
Oestrogen Receptor
Anti-oestrogens
Tamoxifen
Fulvestrant
Aromatase Inhibitors
Letrozole
Anastrozole
Exemestane
Ovarian suppression
Oophorectomy
GnRH agonists (Goserelin)
Larionov &amp; Miller, Treatment strategies, 2010
Endocrine treatment in breast cancer</text>
		</slide>
		<slide index="88" title="" titleNormalized="" src="slide89.swf" size="7695" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset88">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>80</notes>
			<notesNormalized>80</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;80&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Estrogens
Breast cancer growth
Aromatase
HO
O
O
O
Androgens
Aromatase Inhibitors (AIs)
ER+ve</text>
		</slide>
		<slide index="89" title="" titleNormalized="" src="slide90.swf" size="11624" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset89">
			<sounds/>
			<videos/>
			<transitionEffect name="FadeSmoothly" duration="0.7000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>81</notes>
			<notesNormalized>81</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;81&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Estrogens
Breast cancer growth
Aromatase
HO
O
O
O
Androgens
ER+ve
Aromatase Inhibitors (AIs)</text>
		</slide>
		<slide index="90" title="" titleNormalized="" src="slide91.swf" size="5474" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset90">
			<sounds/>
			<videos/>
			<transitionEffect name="FadeSmoothly" duration="0.7000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>82</notes>
			<notesNormalized>82</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;82&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>PDB: 3S79
Ghosh et al, J.Med.Chem , 2012, 55: 8464-8476 
Membrane
Aromatase
Hem
Androgen
3D computer modelling based on X-ray crystallography
Aromatase</text>
		</slide>
		<slide index="91" title="" titleNormalized="" src="slide92.swf" size="5832" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset91">
			<sounds/>
			<videos/>
			<transitionEffect name="FadeSmoothly" duration="0.7000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>82</notes>
			<notesNormalized>82</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;82&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>PDB: 3S79
Ghosh et al, J.Med.Chem , 2012, 55: 8464-8476 
Membrane
Aromatase
Hem
Androgen
3D computer modelling based on X-ray crystallography
Ghosh et al 2016 
PMID: 26689671
Aromatase</text>
		</slide>
		<slide index="92" title="" titleNormalized="" src="slide93.swf" size="157680" advanceOnTime="0" framesCount="384" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset92">
			<sounds/>
			<videos>
				<video id="video3" videoClipId="ispring.resources_3323c138.spr0_183276901" slides="1" repeat="1" volume="0.8000000" posterFrameId="ispring.resources_3323c138.spr2_183276901" playFullScreen="0" hideWhenNotPlaying="0" rewindAfterPlaying="0"/>
			</videos>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands>
				<playVideo frameIndex="0" videoId="video3" startPos="0.0000000"/>
			</videoCommands>
			<animationSteps>
				<step start="0" end="383" playTime="15.9583333" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>83</notes>
			<notesNormalized>83</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;83&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>PDB: 3S79
Ghosh et al, J.Med.Chem , 2012, 55: 8464-8476 
Membrane
Aromatase
Hem
3D computer modelling based on X-ray crystallography
Androgen
Ghosh et al 2016 
PMID: 26689671
Aromatase</text>
		</slide>
		<slide index="93" title="" titleNormalized="" src="slide94.swf" size="39592" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset93">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>84</notes>
			<notesNormalized>84</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;84&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Hong et al, Steroids, 2011, 76(8): 802 - 806 
Membrane
3D computer modelling based on X-ray crystallography
Aromatase &amp; NADPH-reductase</text>
		</slide>
		<slide index="94" title="" titleNormalized="" src="slide95.swf" size="8710" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset94">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>86</notes>
			<notesNormalized>86</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;86&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Pre-menopause
Post-menopause
Ovary and adrenal gland
Peripheral tissues
Adipose, Skin, Muscle (?) … , Tumour itself
Blood
Blood
Androgens
Oestrogens
Aromatase
Cholesterol 
3-4 steps
Ovary
Blood
Blood
Blood
Androgens
Cholesterol 
3-4 steps
Oestrogens
Androgens
Aromatase
Simpson 2003 Journal of Steroid Biochemistry &amp; Molecular Biology 86: 225
Aromatisation within the body</text>
		</slide>
		<slide index="95" title="" titleNormalized="" src="slide96.swf" size="8863" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset95">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>86</notes>
			<notesNormalized>86</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;86&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Pre-menopause
Post-menopause
Ovary and adrenal gland
Peripheral tissues
Adipose, Skin, Muscle (?) … , Tumour itself
Ovary
Simpson 2003 Journal of Steroid Biochemistry &amp; Molecular Biology 86: 225
In post-menopause oestrogens are made in peripheral tissues
Blood
Blood
Androgens
Oestrogens
Aromatase
Cholesterol 
3-4 steps
Blood
Blood
Blood
Androgens
Cholesterol 
3-4 steps
Oestrogens
Androgens
Aromatase
Aromatisation within the body</text>
		</slide>
		<slide index="96" title="" titleNormalized="" src="slide97.swf" size="9618" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset96">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>86</notes>
			<notesNormalized>86</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;86&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Pre-menopause
Post-menopause
Ovary and adrenal gland
Peripheral tissues
Adipose, Skin, Muscle (?) … , Tumour itself
Ovary
Aromatase inhibitors are NOT effective in ovary !
Simpson 2003 Journal of Steroid Biochemistry &amp; Molecular Biology 86: 225
Blood
Blood
Androgens
Oestrogens
Aromatase
Cholesterol 
3-4 steps
AI
Blood
Blood
Blood
Androgens
Cholesterol 
3-4 steps
Oestrogens
Androgens
Aromatase
AI</text>
		</slide>
		<slide index="97" title="" titleNormalized="" src="slide98.swf" size="9799" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset97">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>86</notes>
			<notesNormalized>86</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;86&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Pre-menopause
Post-menopause
Ovary and adrenal gland
Peripheral tissues
Adipose, Skin, Muscle (?) … , Tumour itself
Ovary
Simpson 2003 Journal of Steroid Biochemistry &amp; Molecular Biology 86: 225
Blood
Blood
Androgens
Oestrogens
Aromatase
Cholesterol 
3-4 steps
AI
Blood
Blood
Blood
Androgens
Cholesterol 
3-4 steps
Oestrogens
Androgens
Aromatase
AI
AIs are effective in post-menopause ONLY
Aromatase inhibitors are NOT effective in ovary !</text>
		</slide>
		<slide index="98" title="" titleNormalized="" src="slide99.swf" size="7950" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset98">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>87</notes>
			<notesNormalized>87</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;87&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>3 generations of aromatase inhibitors
Generation
Steroidal
Type I
Non-steroidal
Type II
First - 1970th
Testolactone
Aminoglutethimide
Second - 1980th
Formestane
Fadrozole
Third - 1990th
Exemestane
Anastrozole
Letrozole</text>
		</slide>
		<slide index="99" title="" titleNormalized="" src="slide100.swf" size="13572" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset99">
			<sounds/>
			<videos/>
			<transitionEffect name="FadeSmoothly" duration="0.7000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>88</notes>
			<notesNormalized>88</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;88&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>AIs of the 3rd generation
Letrozole
(Femara, Novartis)
Anastrozole
(Arimidex, AstraZeneca ) 
Exemestane
(Aromasin, Pfizer )
Non
Steroidal
(Type II)
Steroidal
(Type I)
Strong &amp; specific, all bind to catalytic cavity</text>
		</slide>
		<slide index="100" title="" titleNormalized="" src="slide101.swf" size="41940" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset100">
			<sounds/>
			<videos/>
			<transitionEffect name="FadeSmoothly" duration="0.7000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>89</notes>
			<notesNormalized>89</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;89&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Pharmacophore model of non-steroidal AIs
Letrozole
Anastrozole
Neves et al, J.Med.Chem, 2009, 52: 143 - 150</text>
		</slide>
		<slide index="101" title="" titleNormalized="" src="slide102.swf" size="8098" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset101">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>90</notes>
			<notesNormalized>90</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;90&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Inhibitor
Inhibition %
Residual %
Anastrozole
97.3
2.7
Exemestane
97.9
2.1
Letrozole
&gt;99.1
&lt;0.9
Geisler et al Clin Cancer Res 1998:4:2089–93
Geisler et al 2002 PMID 11821457
Effect of 3rd generation AIs on aromatase activity
Total peripheral aromatisation in human body</text>
		</slide>
		<slide index="102" title="" titleNormalized="" src="slide103.swf" size="8311" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset102">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>90</notes>
			<notesNormalized>90</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;90&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Inhibitor
Inhibition %
Residual %
Anastrozole
97.3
2.7
Exemestane
97.9
2.1
Letrozole
&gt;99.1
&lt;0.9
Geisler et al Clin Cancer Res 1998:4:2089–93
Geisler et al 2002 PMID 11821457
Total peripheral aromatisation in human body
Research setting:
a small number of carefully selected and monitored postmenopausal patients
Effect of 3rd generation AIs on aromatase activity</text>
		</slide>
		<slide index="103" title="" titleNormalized="" src="slide104.swf" size="7216" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset103">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>93</notes>
			<notesNormalized>93</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;93&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>hundreds of postmenopausal patients
multi-centre study
Effect of AIs on blood oestrogens
Possible causes of discrepancy with 
the research data in previous slide:
Diversity in biology of patients population non detectable in small pre-clinical studies
Slip-ups in ascertaining of post-menopausal status in real-life clinical practice as opposed to the careful selection in research setting?
Issues with adherence in real-life clinical setting?
Individual differences in drug metabolism?
Mean level of oestradiol in post-menopause w/o aromatase inhibition (Robarge et al 2017 PMID 27943008)
Clinical setting:
Mean level of oestradiol in follicular phase 
(Häggström 2014 Reference ranges for estradiol … during the menstrual cycle - doi:10.15347/wjm/2014.001)
Ingle et al. 2015 Steroids, 99:32
Anastrozole (adjuvant)
log-scale</text>
		</slide>
		<slide index="104" title="" titleNormalized="" src="slide105.swf" size="32721" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset104">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>96</notes>
			<notesNormalized>96</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;96&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Residual oestrogens levels in an adjuvant study
Comparison of Aromatase Inhibitors
Upper quartile of 
post-menopausal oestradiol
w/o aromatase inhibition 
(Robarge et al 2017 PMID 27943008)
Letrozole or 
Anastrozole
Exemestane
K.Elliott et al. Br J Surg. 2014 101:939–948</text>
		</slide>
		<slide index="105" title="" titleNormalized="" src="slide106.swf" size="34978" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset105">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>97</notes>
			<notesNormalized>97</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;97&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Reduction of proliferation in a neo-adjuvant study
Ellis et al, J Clin Oncol. 2011 29(17):2342-9
ACOSOG Z1031 study
P&lt;0.05
Clinical response rate
%
Reduction in proliferation
Ki67, %
Data from Table 1
Panel from Figure 2
63%
75%
69%
-78%
-81%
-87%
Comparison of Aromatase Inhibitors</text>
		</slide>
		<slide index="106" title="" titleNormalized="" src="slide107.swf" size="10672" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset106">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>98</notes>
			<notesNormalized>98</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;98&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Neo-adjuvant treatment as a research tool
Neo-adjuvant treatment (3+ months) 
Indicated to patients with large non-disseminated tumours 
to facilitate surgery or to reduce volume of surgery
Allows sequential biopsies of the same human tumour
before and after treatment
Surgery
Diagnosis
Dissemination
Neo-Adjuvant
Adjuvant
Advanced / Metastatic</text>
		</slide>
		<slide index="107" title="" titleNormalized="" src="slide108.swf" size="89429" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset107">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>99</notes>
			<notesNormalized>99</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;99&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Adding Fulvestrant to AIs
Animal model vs human trial …
Xenograft model (MCF-7 transfected with aromatase)
Clinical trial (advanced setting)
Jelovac et al, 2005, Cancer Res, 65(12):5439-44
Mehta et al ,2012, NEJM, 367(5):435-44
control
fulvestrant
letrozole
Letrozole +
fulvestrant
p=0.049
median survival
41 → 48 months
anastrozole
fulvestrant (250)
anastrozole + 
Tumour volume (%)
Time (weeks)
Time (months)
Survival
Animal models can not capture complexity of human disease</text>
		</slide>
		<slide index="108" title="" titleNormalized="" src="slide109.swf" size="87721" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset108">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>100</notes>
			<notesNormalized>100</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;100&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Letrozole shrinks tumour
 before after 3 months 
MAMMOGRAPHY
ULTRASOUND
 before after 3 months 
Neo-adjuvant treatment shows effects of AIs on human tumours</text>
		</slide>
		<slide index="109" title="" titleNormalized="" src="slide110.swf" size="120094" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset109">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>102</notes>
			<notesNormalized>102</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;102&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Brown staining shows an oestrogen-induced protein (PgR = Progesterone Receptors)
AIs inhibit oestrogen signalling in tumours
Neo-adjuvant treatment shows effects of AIs on human tumours</text>
		</slide>
		<slide index="110" title="" titleNormalized="" src="slide111.swf" size="91155" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset110">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>103</notes>
			<notesNormalized>103</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;103&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Brown staining shows proliferating cells (Ki67)
AIs stop tumour cells proliferation
Pre
10 days
Neo-adjuvant treatment shows effects of AIs on human tumours</text>
		</slide>
		<slide index="111" title="" titleNormalized="" src="slide112.swf" size="185063" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset111">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>104</notes>
			<notesNormalized>104</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;104&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Proliferation quickly goes down and stays low
in most (but not all) human tumours
Miller et al, Endo Rel Cancer 2005, Vol 12: S119-123
% proliferating cell (Ki67)
0
days
10-14
days
3 months
Neo-adjuvant treatment shows effects of AIs on human tumours</text>
		</slide>
		<slide index="112" title="" titleNormalized="" src="slide113.swf" size="28992" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset112">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>110</notes>
			<notesNormalized>110</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;110&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Ovary
(pre-menopause)
Peripheral tissues
(post-menopause)
Breast Cancer Cell
Oestrogen Receptor
Anti-oestrogens
Tamoxifen
Fulvestrant
Aromatase Inhibitors
Letrozole
Anastrozole
Exemestane
Ovarian suppression
Oophorectomy
GnRH agonists (Goserelin)
Larionov &amp; Miller, Treatment strategies, 2010
Endocrine treatment in breast cancer</text>
		</slide>
		<slide index="113" title="" titleNormalized="" src="slide114.swf" size="8253" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset113">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>112</notes>
			<notesNormalized>112</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;112&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Method
Features
Oophorectomy
Simple surgical procedure, absolute efficiency, low morbidity, non-reversible
Irradiation
Issues with reliability and complications
GnRH agonists
Non-invasive, effective, reversible
Current method of choice
Tamoxifen alone or Tamoxifen + Ovarian Suppression
If combined with Ovarian Suppression, Tamoxifen may be changed to an Aromatase Inhibitor
Pre-menopausal ER-positive breast cancer
Current practice for endocrine treatment
Cytotoxic chemotherapy may temporarily suppress ovarian function.
However, it is NOT a method of ovarian suppression because
menses resume after chemotherapy in most young patients (&lt;40yrs).
Note: 
Ovarian Suppression</text>
		</slide>
		<slide index="114" title="" titleNormalized="" src="slide115.swf" size="8230" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset114">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>113</notes>
			<notesNormalized>113</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;113&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Method
Features
Oophorectomy
Simple surgical procedure, absolute efficiency, low morbidity, non-reversible
Irradiation
Issues with reliability and complications
GnRH agonists
Non-invasive, effective, reversible
Current method of choice
Cytotoxic chemotherapy may temporarily suppress ovarian function.
However, it is NOT a method of ovarian suppression because
menses resume after chemotherapy in most young patients (&lt;40yrs).
Note: 
Tamoxifen alone or Tamoxifen + Ovarian Suppression
If combined with Ovarian Suppression, Tamoxifen may be changed to an Aromatase Inhibitor
Current practice for endocrine treatment
Pre-menopausal ER-positive breast cancer
Ovarian Suppression</text>
		</slide>
		<slide index="115" title="" titleNormalized="" src="slide116.swf" size="7733" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset115">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>114</notes>
			<notesNormalized>114</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;114&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Both GNRH Agonists and Antagonists inhibit ovarian function 
either by blocking the signalling directly (antagonists) or by disrupting the pulsatile pattern of GNRH stimulation (agonists)
GNRH is an oligo-peptide hypothalamic hormone
GNRH control over ovaries is mediated by pituitary tropic hormones (FSH, LH)
Glu 
Trp
Ser
His
Leu
Pro
Tyr
Gly
Arg
Gly
Synthetic GNRH agonists and antagonists are made by amino-acid substitutions/modifications
Pituitary
Hypothalamus
Pulsatile secretion of 
GNRH
FSH, LH
Ovaries
Estorgen
Pharmacologic ovarian suppression</text>
		</slide>
		<slide index="116" title="" titleNormalized="" src="slide117.swf" size="17126" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset116">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>115</notes>
			<notesNormalized>115</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;115&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>GNRH is an oligo-peptide hypothalamic hormone
GnRH agonists
Goserelin, Buserelin, Leuprolide, Nafarelin, etc.
GnRH antagonists
Cetrorelix, Ganirelix, Abarelix, Degarelix
Goserelin
(Zoladex, AstraZeneca)

happened to be 
most tested and used 
in breast cancer
GNRH control over ovaries is mediated by pituitary tropic hormones (FSH, LH)
Glu 
Trp
Ser
His
Leu
Pro
Tyr
Gly
Arg
Gly
Synthetic GNRH agonists and antagonists are made by amino-acid substitutions/modifications
Both Agonists and Antagonists are used to inhibit ovarian function 
Pharmacologic ovarian suppression</text>
		</slide>
		<slide index="117" title="" titleNormalized="" src="slide118.swf" size="15616" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset117">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>110</notes>
			<notesNormalized>110</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;110&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Ovary
(pre-menopause)
Peripheral tissues
(post-menopause)
Breast Cancer Cell
Oestrogen Receptor
Anti-oestrogens
Tamoxifen
Fulvestrant
Aromatase Inhibitors
Letrozole
Anastrozole
Exemestane
Ovarian suppression
Oophorectomy
GnRH agonists (Goserelin)
Larionov &amp; Miller, Treatment strategies, 2010
Endocrine treatment in breast cancer
Currently available options</text>
		</slide>
		<slide index="118" title="" titleNormalized="" src="slide119.swf" size="25770" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset118">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>117</notes>
			<notesNormalized>117</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;117&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Ovary
(pre-menopause)
Peripheral tissues
(post-menopause)
Breast Cancer Cell
Oestrogen Receptor
Anti-oestrogens
Tamoxifen
Fulvestrant
Aromatase Inhibitors
Letrozole
Anastrozole
Exemestane
Ovarian suppression
Oophorectomy
GnRH agonists (Goserelin)
Larionov &amp; Miller, Treatment strategies, 2010

What is better?

Endocrine treatment in breast cancer
Currently available options</text>
		</slide>
		<slide index="119" title="" titleNormalized="" src="slide120.swf" size="32948" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset119">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>106</notes>
			<notesNormalized>106</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;106&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Advanced Breast Cancer
Aromatase Inhibitors superiority over Tamoxifen
Mouridsen et al, J Clin Oncol, 2003, 21(11):2101-9.</text>
		</slide>
		<slide index="120" title="" titleNormalized="" src="slide121.swf" size="116063" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset120">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>107</notes>
			<notesNormalized>107</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;107&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Early Breast Cancer
BIG 1-98 study
Regan, Lancet Oncol 2011; 12: 1101–08
Aromatase Inhibitors superiority over Tamoxifen</text>
		</slide>
		<slide index="121" title="" titleNormalized="" src="slide122.swf" size="144443" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset121">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>108</notes>
			<notesNormalized>108</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;108&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Example of a clinical trial: BIG 1-98 study
Regan, Lancet Oncol 2011; 12: 1101–08
Evidence-based medicine is based on clinical trials</text>
		</slide>
		<slide index="122" title="" titleNormalized="" src="slide123.swf" size="9212" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset122">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>109</notes>
			<notesNormalized>109</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;109&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Inhibitor
Neo-adjuvant treatment
Early Breast Cancer
Adjuvant treatment
Advanced breast cancer
Anastrozole
IMPACT
ATAC
TARGET
Exemestane
Semiglazov et al 2005
TEAM
EORTC 10951
Letrozole
P 024
BIG 1-98
P 025
Many trials have confirmed superiority of AIs over TAM
These are just a small fraction of trials in endocrine treatment and resistance.
There are many more completed and on-going: phase I, II, III, post-approval …
Focused on treatment efficacy, tolerability, combination, sequencing …</text>
		</slide>
		<slide index="123" title="" titleNormalized="" src="slide124.swf" size="9383" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset123">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>109</notes>
			<notesNormalized>109</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;109&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Inhibitor
Neo-adjuvant treatment
Early Breast Cancer
Adjuvant treatment
Advanced breast cancer
Anastrozole
IMPACT
ATAC
TARGET
Exemestane
Semiglazov et al 2005
TEAM
EORTC 10951
Letrozole
P 024
BIG 1-98
P 025
Post-menopause …
Only ER+ve patients, of course …
These are just a small fraction of trials in endocrine treatment and resistance.
There are many more completed and on-going: phase I, II, III, post-approval …
Focused on treatment efficacy, tolerability, combination, sequencing …
Many trials have confirmed superiority of AIs over TAM</text>
		</slide>
		<slide index="124" title="" titleNormalized="" src="slide125.swf" size="54574" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset124">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>116</notes>
			<notesNormalized>116</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;116&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>2 months pre-operative treatment
 (STAGE study, Japan)
Masuda et al, Lancet Oncol 2012; 13: 345–52
Response rate (%)
in combination with ovarian suppression !!!
Adjuvant treatment
Pagani et al. 2014 N Engl J Med. 371:107
actually, in pre-menopause- too …
Many trials have confirmed superiority of AIs over TAM</text>
		</slide>
		<slide index="125" title="" titleNormalized="" src="slide126.swf" size="11368" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset125">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>“End of history”
2010 – 2015 : 
1980 - 2000s :
pre 1980s :
2000 – 2010 :
pre-Tamoxifen (= pre-historic) times
Raise and Triumph of Tamoxifen
Dawn of AIs of the 3rd generation
Storyline of Endocrine treatment in BC
AIs take over Tamoxifen in all settings …
(+ ovarian suppression in pre-menopause)
(as it was seen in 2015)</text>
		</slide>
		<slide index="126" title="" titleNormalized="" src="slide127.swf" size="8222" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset126">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>2010 – 2015 : 
“End of history”
1980 - 2000s :
pre 1980s :
2000 – 2010 :
pre-Tamoxifen (= pre-historic) times
Raise and Triumph of Tamoxifen
Dawn of AIs of the 3rd generation
History never ends !
Storyline of Endocrine treatment in BC
AIs take over Tamoxifen in all settings …
(+ ovarian suppression in pre-menopause)
(as it was seen in 2017)</text>
		</slide>
		<slide index="127" title="" titleNormalized="" src="slide128.swf" size="112159" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset127">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>Advanced ER+ve breast cancer, first line treatment
FALCON: Fulvestrant 500mg challenges the AIs domination …
Lancet 2016; 388: 2997–3005</text>
		</slide>
		<slide index="128" title="" titleNormalized="" src="slide129.swf" size="125774" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset128">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>MONARCH2: Fulvestrant + CDK4/6-inhibitors is even better …
JCO: June 3, 2017
Advanced ER+ve breast cancer, resistant to previous endocrine therapy
(we will discuss endocrine resistance during the 2nd part of the seminar)
A paper from
the reading list</text>
		</slide>
		<slide index="129" title="" titleNormalized="" src="slide130.swf" size="92882" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset129">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>PALOMA: CDK4/6 inhibitors are good with AIs too …
N Engl J Med 2016
Advanced ER+ve breast cancer, first line treatment</text>
		</slide>
		<slide index="130" title="" titleNormalized="" src="slide131.swf" size="25925" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset130">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>117</notes>
			<notesNormalized>117</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;117&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Ovary
(pre-menopause)
Peripheral tissues
(post-menopause)
Breast Cancer Cell
Oestrogen Receptor
Anti-oestrogens
Tamoxifen
Fulvestrant
Aromatase Inhibitors
Letrozole
Anastrozole
Exemestane
Ovarian suppression
Oophorectomy
GnRH agonists (Goserelin)

So, what is better?

Endocrine treatment in breast cancer
Currently available options</text>
		</slide>
		<slide index="131" title="" titleNormalized="" src="slide132.swf" size="6350" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset131">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>78</notes>
			<notesNormalized>78</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;78&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>The practice is currently changing …
In 2017 :
It has been substituted by Aromatase Inhibitors in post-menopause
Will soon be substituted by Fulvestrant in pre-menopause too ?
Tamoxifen is still widely used in pre-menopause
Till recently Fulvestrant was used for endocrine-resistant cases only
After FALCON study (2016) Fulvestrant can be used as the 1st line treatment in advanced BC
CDK4/6 inhibitors are becoming a standard addition to AIs and Fulvestrant
Novel ER antagonists are under development to substitute Fulvestrant (discussed later)
Fulvestrant and CDK4/6-inhibitors are challenging the standard practices
Aromatase inhibitors are still widely used in post-menopause
Still the treatment of choice in early breast cancer (adjuvant + neo-adjuvant settings)
Challenged by Fulvestrant 500mg in the advanced (metastatic) setting
Goserelin is optionally added to other treatments in pre-menopause
Optional for tamoxifen, compulsory for AIs (in pre-menopause)</text>
		</slide>
		<slide index="132" title="" titleNormalized="" src="slide133.swf" size="5654" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset132">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>118</notes>
			<notesNormalized>118</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;118&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Selected side effects of endocrine treatment in breast cancer
Adverse
May increase blood clotting &amp; gynaecological cancers
Protective
Improves bone density &amp; lipid profile
Adverse
Decreases bone density (can be controlled by bisphosphonates)
May have negative effect on lipid &amp; cardio-vascular profile
May cause arthralgia (pain in joints)
Tamoxifen
Non-steroidal aromatase Inhibitors
Common for Ovarian suppression, Tam &amp; AIs
Menopausal symptoms: Hot flushes etc.</text>
		</slide>
		<slide index="133" title="" titleNormalized="" src="slide134.swf" size="5918" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset133">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>119</notes>
			<notesNormalized>119</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;119&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Discussing reading list
Endocrine treatment in breast cancer
Breast Cancer
Oestrogen Receptor
Endocrine treatment

Short group task
Endocrine resistance in breast cancer
Impact &amp; current management
Mechanisms of endocrine resistance
Future: biomarker-guided targeted treatment and monitoring
Plan of the seminar</text>
		</slide>
		<slide index="134" title="" titleNormalized="" src="slide135.swf" size="5411" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset134">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>120</notes>
			<notesNormalized>120</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;120&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>I have prepared 3 different tasks 
You will get one of them before the coffee break

During the break: think and talk about it 
(get together with those who got the same task)

After the break 
There will be ~5 min for discussion within groups
(move tables/sits if necessary)

Then each group will have ~5 min to present the answer 
to the rest of the class

This is not for assessment! This is just for discussion 
Group tasks after coffee break</text>
		</slide>
		<slide index="135" title="" titleNormalized="" src="slide136.swf" size="5974" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset135">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>121</notes>
			<notesNormalized>121</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;121&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Example task
A 68-year-old woman noted a lump in the left breast about a month ago; she was referred to the breast cancer clinic, where she was diagnosed with breast cancer. The tumour is 6 cm size with enlarged elastic mobile axillary lymph nodes. Chest X-ray, liver ultrasound and liver function tests show no signs of distant spread. Tumour biopsy confirmed invasive ductal carcinoma. Molecular markers show that tumour is oestrogen receptor positive, progesterone receptor positive, HER2 negative. No family history of breast cancer. Concomitant conditions include acute MI 5 years ago &amp; history of deep vein thrombosis; general condition is good for the patient’s age. 

Present case summary to the class. Compare the treatments below; suggest which of them may be suitable and which is not, why? 

1. Immediate mastectomy; after surgery: radiotherapy, adjuvant Tamoxifen for 5 years + Herceptin for 1 year
2. Neo-adjuvant Letrozole for 3 months, reassessment after 3 months to decide about the surgery type and further treatment
3. Neo-adjuvant Fazlodex for 3 months followed by mastectomy &amp; radiotherapy, then 5 years of adjuvant Fazlodex
Suggest what might be missed in the assessment and treatments?</text>
		</slide>
		<slide index="136" title="" titleNormalized="" src="slide137.swf" size="6342" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset136">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>122</notes>
			<notesNormalized>122</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;122&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Case summary
Answers
Missed assessments
Large non-disseminated tumour in elderly post-menopausal patient
LN+ve, ER+ve, HER-ve 
History of DVT 
Immediate mastectomy; after surgery: radiotherapy, adjuvant Tamoxifen for 5 years + Herceptin for 1 year

Neo-adjuvant Letrozole for 3 months, reassessment after 3 months to decide about the surgery type and further treatment

Neo-adjuvant Faslodex for 3 months followed by mastectomy &amp; radiotherapy, then 5 years of adjuvant Faslodex


?
Bone density assessment is needed to administer letrozole to post-menopausal patient
Bisphosphonates may be needed if low bone density is found.
Example answer</text>
		</slide>
		<slide index="137" title="" titleNormalized="" src="slide138.swf" size="6461" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset137">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>123</notes>
			<notesNormalized>123</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;123&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Case summary
Answers
Missed assessments
Large non-disseminated tumour in elderly post-menopausal patient
LN+ve, ER+ve, HER-ve
History of DVT
Immediate mastectomy; after surgery: radiotherapy, adjuvant Tamoxifen for 5 years + Herceptin for 1 year

Neo-adjuvant Letrozole for 3 months, reassessment after 3 months to decide about the surgery type and further treatment

Neo-adjuvant Faslodex for 3 months followed by mastectomy &amp; radiotherapy, then 5 years of adjuvant Faslodex . May become accepted in future – after relevant neo-adjuvant clinical trials for Faslodex 500mg ?


?
Bone density assessment is needed to administer letrozole to post-menopausal patient
Bisphosphonates may be needed if low bone density is found.
Example answer</text>
		</slide>
		<slide index="138" title="" titleNormalized="" src="slide139.swf" size="5906" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset138">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>124</notes>
			<notesNormalized>124</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;124&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Task 1
A patient has been referred to the breast cancer clinic with suspicion on breast cancer detected on mammography screening. In the upper outer quadrant of the left breast there is a lump ~1 cm in diameter. Ultrasound-guided tumour biopsy confirmed invasive ductal carcinoma. Molecular markers: Estrogen receptor positive, HER2 positive. The patient is 45 years old. The menses are regular. No signs of lymph nodes involvement. No signs of distant spread in liver (liver function tests and ultrasound), lungs (chest X-ray) or bones. No concomitant conditions. 

Present case summary to the class. Compare the treatments below; suggest which of them may be suitable and which is not, why? 

1. Immediate tumour removal by conservative surgery (lumpectomy). After surgery: adjuvant Tamoxifen for 5 years + Herceptin for 1 year. 
2. Mastectomy followed by radiotherapy and a course of adjuvant cytotoxic chemotherapy; Then Tamoxifen + Goserelin for 5 years. 
3. Neo-adjuvant Letrozole for 3 months followed by conservative surgery (sector resection). After surgery: 5 years of adjuvant Letrozole + Herceptin for 1 year. 
Suggest what might be missed in the assessment and treatments?</text>
		</slide>
		<slide index="139" title="" titleNormalized="" src="slide140.swf" size="6637" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset139">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>125</notes>
			<notesNormalized>125</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;125&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Immediate tumour removal by conservative surgery (lumpectomy). After surgery: adjuvant Tamoxifen for 5 years + Herceptin for 1 year. 

Mastectomy followed by radiotherapy and a course of adjuvant cytotoxic chemotherapy; Then Letrozole + Goserelin for 5 years. 

Neo-adjuvant Letrozole for 3 months followed by conservative surgery (sector resection). After surgery: 5 years of adjuvant Letrozole + Herceptin for 1 year. 
Small non-disseminated tumour in pre-menopausal patient. 
LN-ve, ER+ve, HER2+ve. 
Progesterone receptors (PgR) have not been mentioned in the case description. Currently PgR assessment is the standard of practice for breast cancer. PgR brings additional information about the functional state of ER signalling in ER+ve tumours. 
Case summary
Answers
Missed assessments


?
Given the young age, the familial history should had been mentioned in the case description; in case of breast cancer in close relatives, BRCA1/2 tests could be done and treatment may need be modified … 
Task 1</text>
		</slide>
		<slide index="140" title="" titleNormalized="" src="slide141.swf" size="6726" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset140">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>126</notes>
			<notesNormalized>126</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;126&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Immediate tumour removal by conservative surgery (lumpectomy). After surgery: adjuvant Tamoxifen for 5 years + Herceptin for 1 year. 

Mastectomy followed by radiotherapy and a course of adjuvant cytotoxic chemotherapy; Then Letrozole + Goserelin for 5 years. Where is Herceptin?

Neo-adjuvant Letrozole for 3 months followed by conservative surgery (sector resection). After surgery: 5 years of adjuvant Letrozole + Herceptin for 1 year. 
Progesterone receptors (PgR) have not been mentioned in the case description. Currently PgR assessment is the standard of practice for breast cancer. PgR brings additional information about the functional state of ER signalling in ER+ve tumours. 
Answers
Missed assessments


Given the young age, the familial history should had been mentioned in the case description; in case of breast cancer in close relatives, BRCA1/2 tests could be done and treatment may need be modified … 

Small non-disseminated tumour in pre-menopausal patient. 
LN-ve, ER+ve, HER2+ve. 
Case summary
Task 1</text>
		</slide>
		<slide index="141" title="" titleNormalized="" src="slide142.swf" size="5986" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset141">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>127</notes>
			<notesNormalized>127</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;127&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>A 55-year-old woman noted lumps in the right breast. GP referred her to the breast cancer clinic. Mammography found three tumour foci in the right breast ( ~1cm, ~1.5 cm and ~3cm in diameters). Right axillary lymph nodes are enlarged and fixed to surrounding tissues. Chest X-ray shows multiple deposits in lungs. No evidence of deposits in liver (liver function tests &amp; ultrasound are normal). No evidence of brain Mts (CT). Core-biopsy confirmed invasive ductal carcinoma. Molecular markers: Estrogen receptor positive, Progesterone receptor positive, HER2 negative. Menses stopped 5 years ago. No familial history of breast cancer. No concomitant conditions. 

Present case summary to the class. Compare the treatments below; suggest which of them may be suitable and which is not, why? 

1. Mastectomy followed by a course of adjuvant cytotoxic chemotherapy; Then adjuvant tamoxifen for 5 years. 
2. A course of adjuvant cytotoxic chemotherapy; local radiotherapy, then letrozole until progression. 
3. Neo-adjuvant Fulvestrant for 3 months followed by conservative surgery. After surgery: Radiotherapy &amp; 5 years of adjuvant Letrozole + Herceptin for 1 year. 
Suggest what might be missed in the assessment and treatments?
Task 2</text>
		</slide>
		<slide index="142" title="" titleNormalized="" src="slide143.swf" size="6305" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset142">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>128</notes>
			<notesNormalized>128</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;128&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Mastectomy followed by a course of adjuvant cytotoxic chemotherapy; Then adjuvant tamoxifen for 5 years. 

A course of adjuvant cytotoxic chemotherapy; local radiotherapy, then letrozole until progression 

Neo-adjuvant Fulvestrant for 3 months followed by conservative surgery. After surgery: Radiotherapy &amp; 5 years of adjuvant Letrozole + Herceptin for 1 year. 
Disseminated breast cancer in a post-menopausal patient
ER+ve, HER2-ve
Case summary
Answers
Missed assessments



Bone density assessment is needed to administer letrozole to a post-menopausal patient
Missed scan for possible bone metastases (scintigraphy?)
Task 2</text>
		</slide>
		<slide index="143" title="" titleNormalized="" src="slide144.swf" size="5970" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset143">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>127</notes>
			<notesNormalized>127</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;127&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>A 67-year-old woman was referred to the breast cancer clinic by GP because of a lump in upper-outer quadrant in the left breast. Mammography shows tumour of ~ 3.5 cm in diameter. Core-biopsy confirmed invasive ductal carcinoma. The axillary lymph nodes are enlarged but not fixed. No evidence of deposits in liver (liver function tests &amp; ultrasound are normal), lungs (chest x-ray), bones (scintigraphy) or brain (CT). Molecular markers: Estrogen receptor positive, Progesterone receptor positive, HER2 negative. No familial history of breast cancer. History of DVT. Bone scan shows reduced bone density. No other concomitant conditions. 

Present case summary to the class. Compare the treatments below; suggest which of them may be suitable and which is not, why? 

1. Mastectomy followed by a course of adjuvant cytotoxic chemotherapy; Then adjuvant tamoxifen for 5 years. 
2. Mastectomy followed by a course of adjuvant cytotoxic chemotherapy; Then adjuvant letrozole for 5 years. 
3. Neo-adjuvant cytotoxic chemotherapy for 3 months followed by conservative surgery. After surgery: adjuvant cytotoxic chemotherapy, local radiotherapy &amp; 5 years of adjuvant Fulvestrant. 
Suggest what might be missed in the assessment and treatments?
Task 3</text>
		</slide>
		<slide index="144" title="" titleNormalized="" src="slide145.swf" size="6255" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset144">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>130</notes>
			<notesNormalized>130</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;130&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Non-disseminated breast cancer in an elderly post-menopausal patient 
ER+ve, HER2-ve, LN+ve
History of DVT, reduced bone density
Case summary
Answers


1. Mastectomy followed by a course of adjuvant cytotoxic chemotherapy; Then adjuvant tamoxifen for 5 years. 
2. Mastectomy followed by a course of adjuvant cytotoxic chemotherapy and local radiotherapy ; Then adjuvant letrozole for 5 years. 
3. Neo-adjuvant cytotoxic chemotherapy for 3 months followed by conservative surgery (conditional on tumour shrinkage). After surgery: adjuvant cytotoxic chemotherapy, local radiotherapy &amp; 5 years of adjuvant Fulvestrant. 
Missed assessments / treatments
Bisphosphonates should be added to AIs for a post-menopausal patient with low bone density
??
Task 3</text>
		</slide>
		<slide index="145" title="" titleNormalized="" src="slide146.swf" size="6420" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset145">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>130</notes>
			<notesNormalized>130</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;130&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Answers


1. Mastectomy followed by a course of adjuvant cytotoxic chemotherapy; Then adjuvant tamoxifen for 5 years. 
2. Mastectomy followed by a course of adjuvant cytotoxic chemotherapy and local radiotherapy ; Then adjuvant letrozole for 5 years. 
3. Neo-adjuvant cytotoxic chemotherapy for 3 months followed by conservative surgery (conditional on tumour shrinkage). After surgery: adjuvant cytotoxic chemotherapy, local radiotherapy &amp; 5 years of adjuvant Fulvestrant. 
Potentially might be considered in future, if (i) Fulvestrant shows superiority over AIs in adjuvant setting and (ii) conservative surgery is preferable
Missed assessments / treatments
Bisphosphonates should be added to AIs for a post-menopausal patient with low bone density
Non-disseminated breast cancer in an elderly post-menopausal patient 
ER+ve, HER2-ve, LN+ve
History of DVT, reduced bone density
Case summary
Task 3
??</text>
		</slide>
		<slide index="146" title="" titleNormalized="" src="slide147.swf" size="16089" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset146">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>131</notes>
			<notesNormalized>131</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;131&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Ovary
(pre-menopause)
Peripheral tissues
(post-menopause)
Breast Cancer Cell
Oestrogen Receptor
Anti-oestrogens
Tamoxifen
Fulvestrant
Aromatase Inhibitors
Letrozole
Anastrozole
Exemestane
Ovarian suppression
Oophorectomy
GnRH agonists (Goserelin)
Larionov &amp; Miller, Treatment strategies, 2010
Endocrine treatment in breast cancer
Summary of currently available options</text>
		</slide>
		<slide index="147" title="" titleNormalized="" src="slide148.swf" size="5523" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset147">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>132</notes>
			<notesNormalized>132</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;132&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Discussing reading list
Endocrine treatment in breast cancer
Breast Cancer
Oestrogen Receptor
Endocrine treatment
Short group task
Endocrine resistance in breast cancer
Impact &amp; current management
Mechanisms of endocrine resistance
Future: biomarker-guided targeted treatment and monitoring
Plan of the seminar</text>
		</slide>
		<slide index="148" title="" titleNormalized="" src="slide149.swf" size="5476" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset148">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>133</notes>
			<notesNormalized>133</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;133&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>up to 20% Early BC 
Progression on treatment in neo-adjuvant setting (pre-surgical)
Relapses on treatment in adjuvant setting (after surgery)

up to 90% Advanced BC
Progression on treatment (inoperable disease)

Primary (intrinsic)
Progression or no response during neo-adjuvant treatment (pre-surgical)
Relapse within 1-2 years on adjuvant treatment (after surgery)
Progression within 2-6 months in advanced setting

Secondary (acquired)
After an evidence of initial response
Relapse or progression on an endocrine treatment
Endocrine resistance</text>
		</slide>
		<slide index="149" title="" titleNormalized="" src="slide150.swf" size="6885" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset149">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>134</notes>
			<notesNormalized>134</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;134&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Switch to another type of endocrine agent
Molecular profiling and monitoring

Selecting endocrine agent and addition of other targeted agent(s) according to the mechanism of tumour growth and resistance
Surgery, X-ray and Cytotoxic chemotherapy as indicated +
Current: 
based on average evidence
Future: 
personalised precision medicine
Endocrine component
Treatment at endocrine resistance</text>
		</slide>
		<slide index="150" title="" titleNormalized="" src="slide151.swf" size="6648" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset150">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>135</notes>
			<notesNormalized>135</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;135&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Switch to another (type of) endocrine agent
Current approach to endocrine component at resistance
SERM
Tamoxifen
Pure anti-oestrogen
Faslodex
Aromatase Inhibitor
Letrozole, Anastrozole

Exemestane</text>
		</slide>
		<slide index="151" title="" titleNormalized="" src="slide152.swf" size="5534" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset151">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>136</notes>
			<notesNormalized>136</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;136&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Discussing reading list
Endocrine treatment in breast cancer
Breast Cancer
Oestrogen Receptor
Endocrine treatment
Short group task
Endocrine resistance in breast cancer
Impact &amp; current management
Mechanisms of endocrine resistance
Future: biomarker-guided targeted treatment and monitoring
Plan of the seminar</text>
		</slide>
		<slide index="152" title="" titleNormalized="" src="slide153.swf" size="8581" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset152">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>137</notes>
			<notesNormalized>137</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;137&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Patient
Tumour
Study / healthcare
Drugs metabolism
Diversity of other escape mechanisms
Drugs target 
variants
Treatment compliance
At least 20% of poor compliance (or even worse…)
Monitoring drug in blood 
Reduction / control of adverse effects
CYP2D6 variants for Tamoxifen ?
CYP2A6 variants for Letrozole ?
Genotyping of metabolising enzymes
Somatic mutations in ER 
Germ-line mutations in Aromatase
Genotyping of ER and Aromatase genes
Response assessment
ER assessment
Ineffective block of ER signalling
Biomarkers for ER signalling in tumour
Diversity in procedures for ER assessment
1%-10% cut-offs, local pathology practices
Diverse response / resistance criteria
 Different criteria between treatment settings
Discrepancy between clinical &amp; biological response
Hormonal status
Inefficient oestrogen suppression by AIs
Monitoring of oestrogen levels on treatment
Assessment of ovarian function in (early) menopause
Multiple Causes and Aspects of Endocrine Resistance</text>
		</slide>
		<slide index="153" title="" titleNormalized="" src="slide154.swf" size="29408" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset153">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>138</notes>
			<notesNormalized>138</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;138&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Patient
Tumour
Study / healthcare
Drugs metabolism
Diversity of other escape mechanisms
Drugs target 
variants
Treatment compliance
At least 20% of poor compliance (or even worse…)
Monitoring drug in blood 
Reduction / control of adverse effects
CYP2D6 variants for Tamoxifen ?
CYP2A6 variants for Letrozole ?
Genotyping of metabolising enzymes
Somatic mutations in ER 
Germ-line mutations in Aromatase
Genotyping of ER and Aromatase genes
Response assessment
ER assessment
Ineffective block of ER signalling
Biomarkers for ER signalling in tumour
Diversity in procedures for ER assessment
1%-10% cut-offs, local pathology practices
Diverse response / resistance criteria
 Different criteria between treatment settings
Discrepancy between clinical &amp; biological response
Hormonal status
Inefficient oestrogen suppression by AIs
Monitoring of oestrogen levels on treatment
Assessment of ovarian function in (early) menopause



DIVERSITY



Multiple Causes and Aspects of Endocrine Resistance</text>
		</slide>
		<slide index="154" title="" titleNormalized="" src="slide155.swf" size="29954" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset154">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>139</notes>
			<notesNormalized>139</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;139&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Patient
Tumour
Study / healthcare
Drugs metabolism
Diversity of other escape mechanisms
Drugs target 
variants
Treatment compliance
At least 20% of poor compliance (or even worse…)
Monitoring drug in blood 
Reduction / control of adverse effects
CYP2D6 variants for Tamoxifen ?
CYP2A6 variants for Letrozole ?
Genotyping of metabolising enzymes
Somatic mutations in ER 
Germ-line mutations in Aromatase
Genotyping of ER and Aromatase genes
Response assessment
ER assessment
Ineffective block of ER signalling
Biomarkers for ER signalling in tumour
Diversity in procedures for ER assessment
1%-10% cut-offs, local pathology practices
Diverse response / resistance criteria
 Different criteria between treatment settings
Discrepancy between clinical &amp; biological response
Hormonal status
Inefficient oestrogen suppression by AIs
Monitoring of oestrogen levels on treatment
Assessment of ovarian function in (early) menopause



Most of research attention so far …

Hyper-sensitivity to low oestrogens
Cross-talk of ER with other signalling pathways
Balance of proliferation and cell death
ER independent tumour growth
Preservation of stem cells
etc.



Multiple Causes and Aspects of Endocrine Resistance</text>
		</slide>
		<slide index="155" title="" titleNormalized="" src="slide156.swf" size="8640" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset155">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>140</notes>
			<notesNormalized>140</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;140&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Patient
Tumour
Study / healthcare
Drugs metabolism
Diversity of other escape mechanisms
Drugs target 
variants
Treatment compliance
At least 20% of poor compliance (or even worse…)
Monitoring drug in blood 
Reduction / control of adverse effects
CYP2D6 variants for Tamoxifen ?
CYP2A6 variants for Letrozole ?
Genotyping of metabolising enzymes
Somatic mutations in ER 
Germ-line mutations in Aromatase
Genotyping of ER and Aromatase genes
Response assessment
ER assessment
Ineffective block of ER signalling
Biomarkers for ER signalling in tumour
Diversity in procedures for ER assessment
1%-10% cut-offs, local pathology practices
Diverse response / resistance criteria
 Different criteria between treatment settings
Discrepancy between clinical &amp; biological response
Hormonal status
Inefficient oestrogen suppression by AIs
Monitoring of oestrogen levels on treatment
Assessment of ovarian function in (early) menopause
Multiple Causes and Aspects of Endocrine Resistance</text>
		</slide>
		<slide index="156" title="" titleNormalized="" src="slide157.swf" size="8630" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset156">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>141</notes>
			<notesNormalized>141</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;141&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Patient
Tumour
Study / healthcare
Drugs metabolism
Diversity of other escape mechanisms
Drugs target 
variants
Treatment compliance
At least 20% of poor compliance (or even worse…)
Monitoring drug in blood 
Reduction / control of adverse effects
CYP2D6 variants for Tamoxifen ?
CYP2A6 variants for Letrozole ?
Genotyping of metabolising enzymes
Somatic mutations in ER 
Germ-line mutations in Aromatase
Genotyping of ER and Aromatase genes
Response assessment
ER assessment
Ineffective block of ER signalling
Biomarkers for ER signalling in tumour
Diversity in procedures for ER assessment
1%-10% cut-offs, local pathology practices
Diverse response / resistance criteria
 Different criteria between treatment settings
Discrepancy between clinical &amp; biological response
Hormonal status
Inefficient oestrogen suppression by AIs
Monitoring of oestrogen levels on treatment
Assessment of ovarian function in (early) menopause
Multiple Causes and Aspects of Endocrine Resistance</text>
		</slide>
		<slide index="157" title="" titleNormalized="" src="slide158.swf" size="8571" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset157">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>142</notes>
			<notesNormalized>142</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;142&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Patient
Tumour
Study / healthcare
Drugs metabolism
Diversity of other escape mechanisms
Drugs target 
variants
Treatment compliance
At least 20% of poor compliance (or even worse…)
Monitoring drug in blood 
Reduction / control of adverse effects
CYP2D6 variants for Tamoxifen ?
CYP2A6 variants for Letrozole ?
Genotyping of metabolising enzymes
Somatic mutations in ER 
Germ-line mutations in Aromatase
Genotyping of ER and Aromatase genes
Response assessment
ER assessment
Ineffective block of ER signalling
Biomarkers for ER signalling in tumour
Diversity in procedures for ER assessment
1%-10% cut-offs, local pathology practices
Diverse response / resistance criteria
 Different criteria between treatment settings
Discrepancy between clinical &amp; biological response
Hormonal status
Inefficient oestrogen suppression by AIs
Monitoring of oestrogen levels on treatment
Assessment of ovarian function in (early) menopause
Multiple Causes and Aspects of Endocrine Resistance</text>
		</slide>
		<slide index="158" title="" titleNormalized="" src="slide159.swf" size="8632" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset158">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>143</notes>
			<notesNormalized>143</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;143&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Patient
Tumour
Study / healthcare
Drugs metabolism
Diversity of other escape mechanisms
Drugs target 
variants
Treatment compliance
At least 20% of poor compliance (or even worse…)
Monitoring drug in blood 
Reduction / control of adverse effects
CYP2D6 variants for Tamoxifen ?
CYP2A6 variants for Letrozole ?
Genotyping of metabolising enzymes
Somatic mutations in ER 
Germ-line mutations in Aromatase
Genotyping of ER and Aromatase genes
Response assessment
ER assessment
Ineffective block of ER signalling
Biomarkers for ER signalling in tumour
Diversity in procedures for ER assessment
1%-10% cut-offs, local pathology practices
Diverse response / resistance criteria
 Different criteria between treatment settings
Discrepancy between clinical &amp; biological response
Hormonal status
Inefficient oestrogen suppression by AIs
Monitoring of oestrogen levels on treatment
Assessment of ovarian function in (early) menopause
Multiple Causes and Aspects of Endocrine Resistance</text>
		</slide>
		<slide index="159" title="" titleNormalized="" src="slide160.swf" size="8595" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset159">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>144</notes>
			<notesNormalized>144</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;144&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Patient
Tumour
Study / healthcare
Drugs metabolism
Diversity of other escape mechanisms
Drugs target 
variants
Treatment compliance
At least 20% of poor compliance (or even worse…)
Monitoring drug in blood 
Reduction / control of adverse effects
CYP2D6 variants for Tamoxifen ?
CYP2A6 variants for Letrozole ?
Genotyping of metabolising enzymes
Somatic mutations in ER 
Germ-line mutations in Aromatase
Genotyping of ER and Aromatase genes
Response assessment
ER assessment
Ineffective block of ER signalling
Biomarkers for ER signalling in tumour
Diversity in procedures for ER assessment
1%-10% cut-offs, local pathology practices
Diverse response / resistance criteria
 Different criteria between treatment settings
Discrepancy between clinical &amp; biological response
Hormonal status
Inefficient oestrogen suppression by AIs
Monitoring of oestrogen levels on treatment
Assessment of ovarian function in (early) menopause
Multiple Causes and Aspects of Endocrine Resistance</text>
		</slide>
		<slide index="160" title="" titleNormalized="" src="slide161.swf" size="5941" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset160">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>145</notes>
			<notesNormalized>145</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;145&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Ingle et al. 2015 Steroids, 99:32
Range of anastrozole in plasma (ng/mL): 
0
132
33
23
44
Lower quartile
2nd quartile
3rd quartile
Upper quartile
Example of a primary / intrinsic resistance mechanism
649 postmenopausal patients, 4+ weeks of adjuvant Anastrozole
Inefficient oestrogen suppression by AIs</text>
		</slide>
		<slide index="161" title="" titleNormalized="" src="slide162.swf" size="6024" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset161">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>146</notes>
			<notesNormalized>146</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;146&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Example of a primary / intrinsic resistance mechanism
Ingle et al. 2015 Steroids, 99:32
649 postmenopausal patients, 4+ weeks of adjuvant Anastrozole
Mean level of oestradiol in post-menopause w/o aromatase inhibition (Robarge et al 2017 PMID 27943008)
Mean level of oestradiol in follicular phase 
(Häggström 2014 Reference ranges for estradiol … during the menstrual cycle“ doi:10.15347/wjm/2014.001)
Inefficient oestrogen suppression by AIs</text>
		</slide>
		<slide index="162" title="" titleNormalized="" src="slide163.swf" size="6135" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset162">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>146</notes>
			<notesNormalized>146</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;146&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Example of a primary / intrinsic resistance mechanism
Ingle et al. 2015 Steroids, 99:32
649 postmenopausal patients, 4+ weeks of adjuvant Anastrozole
May explain many cases with
intrinsic resistance to AIs …
Inefficient oestrogen suppression by AIs</text>
		</slide>
		<slide index="163" title="" titleNormalized="" src="slide164.swf" size="8592" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset163">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>148</notes>
			<notesNormalized>148</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;148&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Patient
Tumour
Study / healthcare
Drugs metabolism
Diversity of other escape mechanisms
Drugs target 
variants
Treatment compliance
At least 20% of poor compliance (or even worse…)
Monitoring drug in blood 
Reduction / control of adverse effects
CYP2D6 variants for Tamoxifen ?
CYP2A6 variants for Letrozole ?
Genotyping of metabolising enzymes
Somatic mutations in ER 
Germ-line mutations in Aromatase
Genotyping of ER and Aromatase genes
Response assessment
ER assessment
Ineffective block of ER signalling
Biomarkers for ER signalling in tumour
Diversity in procedures for ER assessment
1%-10% cut-offs, local pathology practices
Diverse response / resistance criteria
 Different criteria between treatment settings
Discrepancy between clinical &amp; biological response
Hormonal status
Inefficient oestrogen suppression by AIs
Monitoring of oestrogen levels on treatment
Assessment of ovarian function in (early) menopause
Multiple Causes and Aspects of Endocrine Resistance</text>
		</slide>
		<slide index="164" title="" titleNormalized="" src="slide165.swf" size="64850" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset164">
			<sounds/>
			<videos/>
			<transitionEffect name="FadeSmoothly" duration="0.7000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>62</notes>
			<notesNormalized>62</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;62&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Activating mutations in ERα LBD
PDB 1QKU 
Toy et al 2013 Nat Genetics 45:1439-45
Toy et al 2017 Cancer Discov; 7(3); 277–87
Gangloff M, J Biol Chem. 2001, 276:15059-65
Y537S LBD w/o E2
wt LBD + E2
Detected in at least 10% of ER+ve BC with acquired resistance during endocrine treatment Detected in &lt;1% of primary ER+ve tumours before endocrine treatment 
Example a secondary / acquired resistance</text>
		</slide>
		<slide index="165" title="" titleNormalized="" src="slide166.swf" size="112964" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset165">
			<sounds/>
			<videos/>
			<transitionEffect name="FadeSmoothly" duration="0.7000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>63</notes>
			<notesNormalized>63</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;63&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Toy et al 2013 Nat Genetics 45:1439-45
% xenograft growth
E2 removal
Start of doxycycline
Days
Effect on tumour growth
Activating mutations in ERα LBD</text>
		</slide>
		<slide index="166" title="" titleNormalized="" src="slide167.swf" size="94901" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset166">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>149</notes>
			<notesNormalized>149</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;149&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Vehicle
AZD9496
Tamoxifen
Fulvestrant
Xenograft volume (mm3)
Days of treatment (supplemented with E2)
Weir et al 2016 - AZD9496: an oral estrogen receptor inhibitor that blocks the growth of ER-positive and ESR1-mutant breast tumors in preclinical models. Cancer Res; 76(11); 3307–18
AZD9496-precursor
Hydroxy-Tamoxifen
HO
AZD9496
 hydroxy Tamoxifen
Targeting mutations in ERα LBD: AZD9496</text>
		</slide>
		<slide index="167" title="" titleNormalized="" src="slide168.swf" size="22099" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset167">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>AZD9496
Astra Zeneca
 THIQ40 (Novartis)
Novel ERα “antagonists and degraders” under development
RAD1901
Pfizer
Tamoxifen
 Success of Fulvestrant-500 and discovery of activating ER LBD mutations triggered a new wave of research in oral ER antagonists
Wardell et al 2015
PMID: 26162914
Weir et al 2016
PMID: 27020862
Burks et al 2017, PMID: 28296398</text>
		</slide>
		<slide index="168" title="" titleNormalized="" src="slide169.swf" size="6922" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset168">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>150</notes>
			<notesNormalized>150</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;150&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Balance of proliferation and cell death

Cancer cells proliferation
Hyper-sensitivity to low oestrogens
Cross-talk of ER with other signalling pathways
ER independent tumour growth
Preservation of stem cells
etc.

Cancer cells death
Reduction in apoptosis
etc.
Patient
Tumour
Study / healthcare
Drugs metabolism
Diversity of other escape mechanisms
Drugs target 
variants
Treatment compliance
Response assessment
ERs assessment
Hormonal status
Multiple Causes and Aspects of Endocrine Resistance</text>
		</slide>
		<slide index="169" title="" titleNormalized="" src="slide170.swf" size="122540" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset169">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>151</notes>
			<notesNormalized>151</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;151&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>CDK6
CDK4
NF-kB
AKT
CCND1
CCNE
MYC
mTOR
P21
PTEN
ERK
RAS
PELP1
PRMT1
PI3K
P27
RBB
E2F
AP1
NCOA3
mir 221
mir 222
mir 9
HER2
GATA4
FOXP3
ER
EGFR
IGF1R
Proliferation
HO
O
Estrogen
P53
BCL2
BAK
CASP
XBP1
IRF1
TNF
etc.
Apoptosis and Survival
Oestrogen signalling and endocrine resistance</text>
		</slide>
		<slide index="170" title="" titleNormalized="" src="slide171.swf" size="115902" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset170">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>152</notes>
			<notesNormalized>152</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;152&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>NF-kB
AKT
CCNE
MYC
mTOR
P21
PTEN
ERK
RAS
PELP1
PRMT1
PI3K
P27
AP1
NCOA3
mir 221
mir 222
mir 9
HER2
GATA4
FOXP3
ER
EGFR
IGF1R
Proliferation
HO
O
Estrogen
CDK6
CDK4
CCND1
RBB
E2F
P53
BCL2
BAK
CASP
XBP1
IRF1
TNF
etc.
Apoptosis and Survival
Oestrogen signalling and endocrine resistance</text>
		</slide>
		<slide index="171" title="" titleNormalized="" src="slide172.swf" size="115221" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset171">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>153</notes>
			<notesNormalized>153</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;153&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>NF-kB
AKT
CCNE
MYC
mTOR
P21
PTEN
ERK
RAS
PELP1
PRMT1
PI3K
P27
AP1
NCOA3
mir 221
mir 222
mir 9
HER2
GATA4
FOXP3
ER
EGFR
IGF1R
Proliferation
HO
O
Estrogen
CDK6
CDK4
RBB
E2F
CCND1
Amplified in 10-20% 
of breast cancers
P53
BCL2
BAK
CASP
XBP1
IRF1
TNF
etc.
Apoptosis and Survival
Oestrogen signalling and endocrine resistance</text>
		</slide>
		<slide index="172" title="" titleNormalized="" src="slide173.swf" size="118067" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset172">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>154</notes>
			<notesNormalized>154</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;154&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>NF-kB
AKT
CCNE
MYC
mTOR
P21
PTEN
ERK
RAS
PELP1
PRMT1
PI3K
P27
AP1
NCOA3
mir 221
mir 222
mir 9
HER2
GATA4
FOXP3
ER
EGFR
IGF1R
Proliferation
HO
O
Estrogen
RBB
E2F
CDK6
CDK4
CCND1
Amplified in 15-25% 
of breast cancers
P53
BCL2
BAK
CASP
XBP1
IRF1
TNF
etc.
Apoptosis and Survival
Oestrogen signalling and endocrine resistance</text>
		</slide>
		<slide index="173" title="" titleNormalized="" src="slide174.swf" size="122313" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset173">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>155</notes>
			<notesNormalized>155</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;155&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>NF-kB
AKT
CCNE
MYC
mTOR
P21
PTEN
ERK
RAS
PELP1
PRMT1
PI3K
P27
AP1
NCOA3
mir 221
mir 222
mir 9
HER2
GATA4
FOXP3
ER
EGFR
IGF1R
Proliferation
HO
O
Estrogen
CDK6
CDK4
CCND1
RBB
E2F
Truncated isoform in 
some breast cancers
P53
BCL2
BAK
CASP
XBP1
IRF1
TNF
etc.
Apoptosis and Survival
Oestrogen signalling and endocrine resistance</text>
		</slide>
		<slide index="174" title="" titleNormalized="" src="slide175.swf" size="110422" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset174">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>156</notes>
			<notesNormalized>156</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;156&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>NF-kB
AKT
CCNE
MYC
mTOR
P21
PTEN
ERK
RAS
PELP1
PRMT1
PI3K
P27
AP1
NCOA3
mir 221
mir 222
mir 9
HER2
GATA4
FOXP3
ER
EGFR
IGF1R
Proliferation
HO
O
Estrogen
CDK6
CDK4
CCND1
RBB
E2F
Overexpressed in
some breast cancers
P53
BCL2
BAK
CASP
XBP1
IRF1
TNF
etc.
Apoptosis and Survival
Oestrogen signalling and endocrine resistance</text>
		</slide>
		<slide index="175" title="" titleNormalized="" src="slide176.swf" size="103709" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset175">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>157</notes>
			<notesNormalized>157</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;157&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>NF-kB
AKT
CCNE
MYC
mTOR
P21
PTEN
ERK
RAS
PELP1
PRMT1
PI3K
P27
AP1
NCOA3
mir 221
mir 222
mir 9
HER2
GATA4
FOXP3
ER
EGFR
IGF1R
Proliferation
HO
O
Estrogen
CDK6
CDK4
CCND1
RBB
E2F
Amplified in ~10% 
of ER+ve breast cancers
often amplified in ER-ve too !
P53
BCL2
BAK
CASP
XBP1
IRF1
TNF
etc.
Apoptosis and Survival
Oestrogen signalling and endocrine resistance</text>
		</slide>
		<slide index="176" title="" titleNormalized="" src="slide177.swf" size="97725" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset176">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>158</notes>
			<notesNormalized>158</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;158&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>NF-kB
AKT
CCNE
MYC
mTOR
P21
PTEN
ERK
RAS
PELP1
PRMT1
PI3K
P27
AP1
NCOA3
mir 221
mir 222
mir 9
HER2
GATA4
FOXP3
ER
EGFR
IGF1R
Proliferation
HO
O
Estrogen
P
CDK6
CDK4
CCND1
RBB
E2F
Amplified in ~10% 
of ER+ve breast cancers
often amplified in ER-ve too !
P53
BCL2
BAK
CASP
XBP1
IRF1
TNF
etc.
Apoptosis and Survival
Oestrogen signalling and endocrine resistance</text>
		</slide>
		<slide index="177" title="" titleNormalized="" src="slide178.swf" size="181297" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset177">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>159</notes>
			<notesNormalized>159</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;159&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>NF-kB
AKT
CCNE
MYC
mTOR
P21
PTEN
ERK
RAS
PELP1
PRMT1
PI3K
P27
AP1
NCOA3
mir 221
mir 222
mir 9
HER2
P53
BCL2
BAK
CASP
XBP1
IRF1
TNF
etc.
GATA4
FOXP3
ER
EGFR
IGF1R
Proliferation
Apoptosis and Survival
HO
O
Estrogen
CDK6
CDK4
CCND1
RBB
E2F
Oestrogen signalling and endocrine resistance</text>
		</slide>
		<slide index="178" title="" titleNormalized="" src="slide179.swf" size="153259" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset178">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>160</notes>
			<notesNormalized>160</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;160&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>NF-kB
AKT
CCNE
MYC
mTOR
P21
PTEN
ERK
RAS
PELP1
PRMT1
PI3K
P27
AP1
NCOA3
mir 221
mir 222
mir 9
HER2
GATA4
FOXP3
ER
EGFR
IGF1R
Proliferation
HO
O
Estrogen
CCND1
RBB
E2F
CDK6
CDK4
Everolimus (afinitor) Novartis
CDK4/6 inhibitors
P53
BCL2
BAK
CASP
XBP1
IRF1
TNF
etc.
Apoptosis and Survival
Herceptin (trastuzumab) Genentech
Approved targeted treatments</text>
		</slide>
		<slide index="179" title="" titleNormalized="" src="slide180.swf" size="65516" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset179">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>161</notes>
			<notesNormalized>161</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;161&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Combining endocrine treatment with other targeted agents
Turner et al. 2015 N Engl J Med. 373:209
Fulvestrant + Palbociclib (CDK4/6 inhibitor)
Advanced breast cancer</text>
		</slide>
		<slide index="180" title="" titleNormalized="" src="slide181.swf" size="47761" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset180">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>162</notes>
			<notesNormalized>162</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;162&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Letrozole + Trastuzumab (HER2 inhibitor)
ER+ve HER2+ve advanced breast cancer
J. Huober et al. 2012 The Breast 21:27
combining endocrine treatments with new targeted agents
Biomarker-guided</text>
		</slide>
		<slide index="181" title="" titleNormalized="" src="slide182.swf" size="45083" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset181">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>164</notes>
			<notesNormalized>164</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;164&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Response rate %
(ultrasound)
Selected mechanistic markers
PIK3CA mutations
Assessment of 
companion biomarkers
Clinical assessment
Exploration of 
molecular mechanisms
Letrozole + Everolimus (mTOR inhibitor) 
4 months pre-operative treatment
P=0.04
Combination
Letrozole alone
58%
47%
Baselga, 2009, JCO, 27:2630
Reduction in proliferation
(% Ki67)
Changes in each marker
(arbitrary units)
combining endocrine treatments with new targeted agents
Biomarker-guided</text>
		</slide>
		<slide index="182" title="" titleNormalized="" src="slide183.swf" size="16152" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset182">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>66</notes>
			<notesNormalized>66</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;66&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Ovary
(pre-menopause)
Peripheral tissues
(post-menopause)
Breast Cancer Cell
Oestrogen Receptor
Anti-oestrogens
Tamoxifen
Faslodex
Aromatase Inhibitors
Letrozole
Anastrozole
Exemestane
GnRH agonists (Goserelin)
e.g. Fulvestrant 
or a new ER-antagonist/degrader
+ 
CDK4/6 inhibitor
or trastuzumab, or everolimus, or other
+
Molecular tests and monitoring
Emerging new strategy in endocrine treatment of breast cancer
Biomarker guided
combination of endocrine treatments with targeted agents</text>
		</slide>
		<slide index="183" title="" titleNormalized="" src="slide184.swf" size="5587" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset183">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>165</notes>
			<notesNormalized>165</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;165&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Discussing reading list
Endocrine treatment in breast cancer
Breast Cancer
Oestrogen Receptor
Endocrine treatment
Short group task
Endocrine resistance in breast cancer
Impact &amp; current management
Diversity of mechanisms
Future: biomarker-guided targeted treatment and monitoring
Plan of the seminar</text>
		</slide>
		<slide index="184" title="" titleNormalized="" src="slide185.swf" size="11147" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset184">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>166</notes>
			<notesNormalized>166</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;166&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Routinely measured molecular biomarkers
Routinely measured molecular biomarkers
ER
PgR
Only ER+ve tumours respond to treatment
ER-rich PgR+ve tumours respond belter
However, ER-poor and PgR-ve still may respond
HER2
Co-expression of ER and HER2 is not common
HER2+ve tumours have worse prognosis
HER2+ve tumours require addition of Herceptin
Ki67
Measures proliferation in tumour
High proliferation on treatment indicates poor response
Translational and experimental signatures
Translational and experimental signatures
SET
Symmans et al 2010 J Clin Oncol 28:4111
Sensitivity to Endocrine Therapy (details on the next slide)
Multi-gene expression signature (165 genes)
Exploratory signature related to prognosis
PEPI
Ellis et al 2008 J Natl Cancer Inst. 100:1380
Preoperative Endocrine Prognostic Index
Includes tumour size, lymph nodes, grede, ER, Ki67
Extrapolates neo-adjuvant response to adjuvant setting
Endopredict
Kronenwett et al 2012 BMC Cancer 12:456
Multi-gene expression signature (11 genes)
Estimates prognosis for adjuvant endocrine treatment
Signatures from Edinburgh Breast Unit
Miller et al 2009 J Clin Oncol 27:1382
Turnbull et al 2015 J Clin Oncol 33:2270
Multi-gene expression signatures (4 and 205 genes)
Look at pre-treatment and on 2-weeks of treatment
Predict neo-adjuvant response after 3 months 
Selected biomarkers for endocrine treatment</text>
		</slide>
		<slide index="185" title="" titleNormalized="" src="slide186.swf" size="81383" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset185">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>167</notes>
			<notesNormalized>167</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;167&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Genomic index for sensitivity to endocrine therapy (SET)
Expression of 165 ER-related genes instead of the single ER
Relapse-free survival in tamoxifen-treated (ER+ve) tumours
Symmans, 2010, J Clin Oncol 28:4111-4119
Low activity of ER-signalling 
despite the presence of ER? 
Biomarkers development: example 1</text>
		</slide>
		<slide index="186" title="" titleNormalized="" src="slide187.swf" size="5659" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset186">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>168</notes>
			<notesNormalized>168</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;168&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Breast-Cancer specific Survival 
&gt;90% accuracy for 
neo-adjuvant response
4-gene predictor of neo-adjuvant response to Letrozole
that includes gene expression changes observed after 2 weeks of treatment
Arran K. Turnbull et al. JCO 2015;33:2270-2278
Detecting early response after short time treatment
Biomarkers development: example 2</text>
		</slide>
		<slide index="187" title="" titleNormalized="" src="slide188.swf" size="43779" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset187">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>168</notes>
			<notesNormalized>168</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;168&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Breast-Cancer specific Survival 
&gt;90% accuracy for 
neo-adjuvant response
4-gene predictor of neo-adjuvant response to Letrozole
that includes gene expression changes observed after 2 weeks of treatment
Arran K. Turnbull et al. JCO 2015;33:2270-2278
Detecting early response after short time treatment
Early detecting resistance, but not the mechanism!
Biomarkers development: example 2</text>
		</slide>
		<slide index="188" title="" titleNormalized="" src="slide189.swf" size="150181" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset188">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>170</notes>
			<notesNormalized>170</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;170&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Detecting of resistance mechanisms in individual tumours
Simultaneous assessment of multiple pathways
at the time of relapse/progression
Larionov &amp; Miller 2015 ISBN 978-3-319-17971-1, Fig 10.4
PIK3CA
High activity
Low activity
60 endocrine resistant tumours at the time of resistance</text>
		</slide>
		<slide index="189" title="" titleNormalized="" src="slide190.swf" size="117846" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset189">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>171</notes>
			<notesNormalized>171</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;171&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Progression-free survival (PFS) in SoFEA trial
by ESR1 mutation status detected in ctDNA
Charlotte Fribbens et al. 2016
doi:10.1200/JCO.2016.67.3061
Mutated ESR1
detected in ctDNA
No mutations in ESR1
detected in ctDNA
“Liquid biopsy” : monitoring markers in circulating tumour DNA
Simple idea, but yet challenging technique</text>
		</slide>
		<slide index="190" title="" titleNormalized="" src="slide191.swf" size="6091" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset190">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>172</notes>
			<notesNormalized>172</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;172&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Discussing reading list
Endocrine treatment in breast cancer
Breast Cancer
Oestrogen Receptor

Endocrine treatment

Short group task
Endocrine resistance in breast cancer
Impact &amp; current management
Diversity of mechanisms
Future: biomarker-guided targeted treatment and monitoring
Plan of the seminar</text>
		</slide>
		<slide index="191" title="" titleNormalized="" src="slide192.swf" size="74248" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset191">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>172</notes>
			<notesNormalized>172</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;172&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Discussing reading list
Endocrine treatment in breast cancer
Breast Cancer
Oestrogen Receptor

Endocrine treatment

Short group task
Endocrine resistance in breast cancer
Impact &amp; current management
Diversity of mechanisms
Future: biomarker-guided targeted treatment and monitoring
Plan of the seminar</text>
		</slide>
		<slide index="192" title="" titleNormalized="" src="slide193.swf" size="82050" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset192">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>175</notes>
			<notesNormalized>175</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;175&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Endocrine treatment in breast cancer

Breast Cancer
Oestrogen Receptor
Endocrine treatment
Questions ?
al720@medschl.cam.ac.uk 
Endocrine resistance in breast cancer

Impact &amp; current management
Diversity of mechanisms
Future: biomarker-guided targeted treatment</text>
		</slide>
	</slides>
</presentation>
